Drug, bio-affecting and body treating compositions inventions 07/08

20080181847 - Targeted imaging and/or therapy using the staudinger ligation: The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological... Agent: Philips Intellectual Property & Standards

20080181848 - Method to detect dopamine receptors in the functional d2high state: This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO in the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state... Agent: Bereskin And Parr

20080181850 - Biomarkers for prostate cancer: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the prostate. In particular, the present invention provides compositions and methods for using neuroligin biomarkers (e.g., NLGN-4Y) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy).... Agent: Casimir Jones, S.c.

20080181849 - Methods, kits and compositions comprising crotamine: Further, the invention refers to a kit comprising crotamine as a reagent to: (i) transfect or carry molecules to the surface, cytoplasm or nucleus of the cell or (ii) identify and select actively proliferating cells in a homogeneous and/or mixed cell population, particularly the ones originated from the umbilical cord... Agent: Arent Fox LLP

20080181852 - Multi-functional drug carriers: Various biodegradable polyglutamate-amino acids comprising recurring units of the general formulae (I) and (II) are prepared. Such polymers are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications.... Agent: Knobbe Martens Olson & Bear LLP

20080181851 - Photoacoustic contrast agents for molecular imaging: Compositions of photoacoustic tomography (PAT) contrast agents, and methods of achieving contrast enhancement and amplification of photo-induced acoustic signal for in vivo photoacoustic imaging of animals and human subjects are provided. Contrast agents of interest are organic-based agents, which may be targeted or non-targeted, e.g. protein-based and/or lipid-based molecules, in... Agent: Bozicevic, Field & Francis LLP

20080181853 - Nanobubbles useful as an ultrasonic contrast agent for the lymphatic system: A composition is provided accompanying nanoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes.... Agent: Dechert LLP

20080181854 - Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides: c

20080181855 - Tooth whitener and maintenance with bleach bumpers: A tooth whitening and maintenance system and method and a system and method for protecting the gums.... Agent: Weiss & Weiss

20080181857 - Dental flosses incorporating active agents: Disclosed is a dental floss formed from at least one fiber and incorporating a polyphosphate salt.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080181856 - Dentifrice containing zinc ions and polyphosphate ions: The invention includes a dentifrice composition that comprises a zinc ion source, a polyphosphate ion source, an anethole, and a silica. The silica has a mean particle size of about 5 to about 12 microns, an Einlehner hardness of about 1 to about 20, and an oil absorption of about... Agent: Colgate-palmolive Company

20080181859 - Novel block (co)polymers, compositions containing them, method of treatment and method of preparation: e

20080181858 - Sunscreen compositions: Sunscreen compositions comprising one or more sunscreen agents (inorganic and combinations of inorganic and organic), one or more film forming polymers (synthetic or naturally derived), and heat treated xanthan gum. The sunscreen composition provides higher pre- and post-immersion SPF values, as well as a means for reducing the amount of... Agent: National Starch And Chemical Company

20080181860 - Polyphenol-based composition, and methods and systems for its preparation: A system for preparing a polyphenol containing formulation includes a first component which is a polyphenol and a second component which is the solvent system for the polyphenol. The solvent system includes water and a surfactant which is an ester of a dicarboxylic acid. The components are maintained separately from... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080181861 - Super-low fouling sulfobetaine and carboxybetaine materials and related methods: Super-low fouling sulfobetaine and carboxybetaine materials, super-low fouling surfaces and methods of making the surfaces coated with sulfobetaine and carboxybetaine materials, and devices having the super-low fouling surfaces.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080181862 - Quaternary ammonium functionalized cross-linked polyalkylsiloxanes with anti-fouling activity: Functionalized cross-linked polysiloxanes, such as quaternary ammonium terminated cross-linked polyalkylsiloxanes are described herein. The functionalized cross-linked polysiloxanes may be used in an antifouling composition to prevent biological fouling in aqueous and/or marine environments.... Agent: Foley & Lardner LLP

20080181863 - Method and composition for attracting fruit flies to traps: This invention relates to a novel method of attracting and trapping Drosophila species and a composition therefor. A method of attracting flies in the family Drosophilidae which comprises preparing an attractant which is a combination of a moistening agent, yeast and dried and powdered vegetable matter host substrate, including (but... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080181864 - Methods and products related to metabolic interactions in disease: The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.... Agent: Wolf Greenfield & Sacks, P.C.

20080181865 - Methods of treating neurological conditions with hematopoeitic growth factors: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080181866 - Amido anti-viral compounds: Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R3, X, V, W, T, Z, R, Y1, and... Agent: Foley & Lardner LLP

20080181868 - Macrocylic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080181867 - Process for manufacturing ophthalmic oil-in-water emulsions: The present invention relates to new processes for the preparation of oil-in-water emulsions useful in ophthalmic applications. In particular, processes are provided that include preparing a pre-concentrate of the oil-in-water emulsion, and diluting the pre-concentrate obtained to form the desired oil-in-water emulsion. The present invention also provides pharmaceutical compositions comprising... Agent: Young & Thompson

20080181869 - Therapeutics to facilitate cell transplantation for liver disease: The present invention provides compositions, formulations and methods for treating liver diseases related to tissue inflammation and progressive fibrosis, e.g., progressive liver fibrosis following either chronic or acute injury. The compositions of the invention provide the use of therapeutic agents as an adjunct therapy to transplantation of cell populations capable... Agent: Dianna Devore Jiva Biosciences, Inc.

20080181872 - Aav vectors encoding superoxide dismutase: The invention relates to adeno-associated virus (AAV) vectors encoding superoxide dismutase (SOD), where the AAV vector encoding SOD (AAV-SOD) may be used to deliver the SOD gene to target cells. The target cells may be within a subject having a disease or condition for which delivery of SOD to the... Agent: Genzyme Corporation Legal Department

20080181870 - Combined gene therapy for the treatment of macroscopic gliomas: Described herein are compositions and methods for the treatment of cancer, and particularly brain cancer (e.g., glioma) in a mammal. In various embodiments of the invention, a combined therapeutic approach including TK with systemic ganciclovir administration and Flt3L are used in connection with gene therapeutic techniques or direct peptide injection... Agent: Davis Wright Tremaine LLP/los Angeles

20080181871 - Focal calcium channel modulation: Disclosed is an invention for focally modulating the activity of a calcium channel in a mammal. In one aspect, the invention features a method that includes contacting a pre-determined tissue or organ region with a nucleic acid sequence encoding a GEM protein or a variant thereof to express the GEM... Agent: Banner & Witcoff, Ltd.

20080181874 - Cell composition and method for treating cancer: The invention provides, in part, novel cell compositions derived from tumor cell lines. Included are an AKCV-1 cell line deposited under ATCC ______, an AKCV-1-GM cell deposited under ATCC ______, and an AKCV-1 cell that is transfected with interferon alpha. Also provided is a cell composition comprising a tumor cell... Agent: Stemedica Cell Technologies, Inc

20080181875 - Use of cyclophilin as antioxidant and prevention of cyclosporin a-induced toxicity in cell transplantation by overexpression of cyclophilin: Disclosed is a cyclophilin protein with PPIase activity functioning as an antioxidant. When being overexpressed in transplanted cells, the cyclophilin protein remarkably reduces the cytotoxicity induced by cyclosporin A or its analogues so that it can greatly improve the success rate in transplantation. Also, disclosed is a composition useful to... Agent: Lucas & Mercanti, LLP

20080181873 - Prolactin induced increase in neural stem cell numbers: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells.... Agent: Fish & Richardson P.C.

20080181876 - Methods for treating acute and subchronic pain: Methods of potentiating opioid-induced analgesia in a subject by administration of a phosphodiesterase (PDE) inhibitor or glial attenuator are described. In particular, the present invention is directed to methods of treating or preventing acute or subchronic pain by administration of a PDE inhibitor or glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine),... Agent: Robins & Pasternak LLP

20080181878 - Degradation-resistant fibrinogen sealants: Provided are degradation-resistant fibrinogen sealants comprising a first composition comprising one or more of fibrinogen γA/γ′ heterodimers and/or fibrinogen γ′/γ′ homodimers and a second composition comprising thrombin and, optionally, degradation-resistant fibrinogen sealants disclosed herein may further comprise Factor XIII and calcium. Degradation-resistant fibrinogen sealants are suitable for the treatment of... Agent: Dann, Dorfman, Herrell & Skillman

20080181879 - Fibrin gel for controlled release of tgf-beta and uses thereof: The present invention relates, in general, to fibrin sealants, which contain transforming growth factor-beta (TGF-β) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, such as bone and cartilage disorders, soft tissue disorders and cardiovascular diseases.... Agent: Baxter Healthcare Corporation Law Department - 1d-15

20080181880 - Method for fostering bone formation and preservation: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any... Agent: Ostrolenk Faber Gerb & Soffen

20080181877 - Method for monitoring the effect of compounds on foxc2 expression: The present invention relates to a method for monitoring/detecting compounds capable to regulate the transcription and/or expression of the forkhead transcription factor Foxc2, which compounds may be useful for the treatment of obesity related diseases and diabetes. The screening for the compounds has been performed in recombinant mouse cells containing... Agent: Oppedahl Patent Law Firm LLC - Wslg

20080181882 - Neurgulin 1 (nrg1) - erbb4 signaling as a target for the treatment of schizophrenia: This invention relates to methods and compositions for the treatment of schizophrenia. Specifically, provided herein are methods and compositions for the treatment of schizophrenia by modulating the effect of Neuregulin-1 on the stimulation of erbB and its subsequent effect on schizophrenic prefrontal cortex.... Agent: Pearl Cohen Zedek Latzer, LLP

20080181883 - Purified antigen for alzheimer's disease and methods of obtaining and using same: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080181884 - Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies: The present invention relates to novel compositions and preparations that are effective antifungal agents, and a novel antibody which can be incorporated into the compositions and preparations.... Agent: Jones Day

20080181881 - Treatment of insulin resistance: Disclosed are a method of for treating insulin resistance and a method identifying a compound for treating insulin resistance.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080181891 - Modified human igf-ir antibodies: The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germline framework amino acid residues which replace one... Agent: Pfizer Inc

20080181887 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant... Agent: Johnathan Klein-evans

20080181890 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080181886 - Polypeptides that bind baff and/or april: The present invention relates to novel polypeptides and TACI variants that bind APRIL, novel polypeptides and TACI variants that bind BAFF, nucleic acid molecules encoding the polypeptides, host cells comprising the nucleic acid molecules, compositions comprising the polypeptides or nucleic acid molecules, and methods of using the polypeptides and nucleic... Agent: Clark & Elbing LLP

20080181888 - Polypeptides that bind br3 and uses thereof: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.... Agent: Clark & Elbing LLP

20080181889 - Prevention of chlamydia infection using a protective antibody: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The compositions include EMP2 nucleic acids and polypeptides as... Agent: Townsend And Townsend And Crew, LLP

20080181885 - Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer: A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 202P5A5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 202P5A5 gene or... Agent: Agensys C/o Morrison & Foerster LLP

20080181892 - Binding domain fusion protein: The present invention relates to constructs and methods for the treatment of diseases, disorders and conditions, including those relating to or involving autoimmune disorders, inflammation, bacterial, fungal, and viral infections, and diseases caused by or involving uncontrolled or abnormal proliferation of cells, including cancer.... Agent: Marshall, Gerstein & Borun LLP

20080181893 - Therapeutic methods for treating vascular eye disorders with dii4 antagonists: A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch... Agent: Regeneron Pharmaceuticals, Inc

20080181894 - Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy: The present invention relates to methods using newly identified cancer related polynucleotides and the polypeptides encoded by these polynucleotides. The invention further relates to the use of such “cancer antigens” for diagnosing cancer and cancer metastases. The invention relates to the use of these cancer antigens employing expression vectors, host... Agent: Cermak Kenealy & Vaidya LLP

20080181896 - Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers: A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes... Agent: National Institutes Of Health

20080181895 - Sp16 protein: The invention provides cDNAs which encodes a signal peptide-containing proteins. It also provides for the use of a cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model... Agent: Foley And Lardner LLP Suite 500

20080181897 - G-csf receptor agonist antibodies and screening method therefor: The invention relates to agonist molecules which specifically bind to or interact with human G-CSF receptor and dimerize the receptor or activate phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation. Such agonist molecules include monoclonal antibodies, or fragments, homologues or analogues thereof, or peptides or... Agent: Nikolaos C. George Jones Day

20080181899 - Human antibodies to human delta like ligand 4: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDII4) and blocks hDII4 binding to a Notch receptor. The human anti-hDII4 antibody or antibody fragment binds hDII4 with an affinity of ≦500 pM, as measured by surface plasmon resonance.... Agent: Regeneron Pharmaceuticals, Inc

20080181898 - Wise/sost nucleic acid sequences and amino acid sequences: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot... Agent: Kevin C. Hooper, Esq. Bryan Cave LLP

20080181900 - Vascular endothelial cell growth factor antagonists: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.... Agent: Genentech, Inc.

20080181902 - Prevention and treatment of alzheimer's disease: The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with... Agent: Ginger R. Dreger, Esq. Goodwin Procter LLP

20080181901 - Protein modulator of the plasma membrane na,k-atpase: This invention relates to an isolated protein MONaKA and methods of its use. Specifically, the invention is directed to a protein that modulates the Na,K-ATPase and glutamate transporters, by binding to the b-subunit of the plasma membrane Na,K-ATPase (Na pump).... Agent: Pearl Cohen Zedek Latzer, LLP

20080181903 - Conjugate of natriuretic peptide and antibody constant region: The present application describes a conjugate between a natriuretic peptide, such as urodilatin, and the constant region of an immunoglobulin or a fragment thereof. Also described are compositions comprising the conjugate and methods for using the conjugate.... Agent: Townsend And Townsend And Crew LLP

20080181904 - Adipocyte complement related protein homolog zacrp2: The present invention relates to polynucleotide and polypeptide molecules for zacrp2, a novel member of the family of proteins bearing a collagen-like domain and a Clq domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention... Agent: Zymogenetics, Inc. Intellectual Property Department

20080181905 - Nanoemulsion vaccines: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and... Agent: Casimir Jones, S.c.

20080181907 - Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia: The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they... Agent: Hunton & Williams LLP Intellectual Property Department

20080181906 - Polyvalent immunogen: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20080181908 - Genes and proteins, and their use: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080181909 - Chimeric immunomodulatory compounds and methods of using the same: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.... Agent: Morrison & Foerster LLP

20080181910 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Tracey S. Truitt Erickson & Kleypas, L.L.C.

20080181911 - Use of an influenza virus, an oil-in-water emulsion adjuvant, to induce cd4 t-cell and/or improved b-memory cell response: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease. In particular the invention relates to vaccine formulations comprising an oil-in-water emulsion adjuvant and optionally 3D-MPL, their use in medicine, in particular their use in augmenting immune responses to influenza antigens, and to methods... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080181912 - Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses: The invention relates to feline IGF-1, to the nucleotide sequence encoding this protein and to the use of IGF-1 as adjuvant for the vaccination of cats, in particular against the feline retroviruses FIV and FeLV. IGF-1 may be used in the form of protein or may be expressed in vivo... Agent: Frommer Lawrence & Haug

20080181913 - Sugar immunogens: Disclosed are compositions and methods useful for inducing an immunogenic response in a subject or host. In particular, the compositions and methods may be directed to carbohydrate HIV vaccines and to methods of producing a carbohydrate HIV vaccine by introducing antigenic sugars into mimics of the glycans of the HIV... Agent: Foley And Lardner LLP Suite 500

20080181914 - Novel vaccine composition: An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilised in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may comprise a micelle modifying excipient, for example α-tocopherol or a derivative thereof... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080181915 - Cd40 ligand adjuvant for respiratory syncytial virus: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a... Agent: Klarquist Sparkman, LLP

20080181916 - Canine lyme disease vaccine: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080181917 - Methods for therapeutic treatment of carpal tunnel syndrome: A method of treating and/or preventing carpal tunnel syndrome (CTS) is provided, comprising administering a therapeutically effective amount of a botulinum toxin to a patient in need thereof or a patient at risk for development of CTS. More specifically, the method includes one or more injections of a botulinum toxin... Agent: Klauber & Jackson

20080181918 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20080181919 - Shiunko nanomicell for skin treatment and preparation method for the same: The present invention provides a nanomicell for a skin, and the nanomicell includes an oil substance, an extract of a Angelica Radix, an extract of a Lithospermum Radix, and a phospholipid layer. The extract of a Angelica Radix is formed by extracting the Angelica Radix with the oil substance, and... Agent: Volpe And Koenig, P.C.

20080181920 - Cosmetic preparation against skin pigmentation: A cosmetic preparation comprising one or more compounds selected from salicylic acid and salts thereof and glycolic acid and salts thereof and one or more pigments selected from titanium dioxide pigments and zinc oxide pigments. This Abstract is not intended to define the invention disclosed in the specification, nor intended... Agent: Greenblum & Bernstein, P.L.C

20080181921 - Multiple layered pigments exhibiting color travel: c

20080181922 - Physical mode of action pesticide: A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polysaccharide in a concentration of from 0.10 to about 0.70 wt. %, a surfactant, a co-solvent and a diluent in a hydrocolloid... Agent: Hedman & Costigan P.C.

20080181923 - Inhibition of bacterial biofilms with imidazole derivatives: Disclosure is provided for imidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20080181925 - Compositions and methods for enzymatic detachment of bacterial and fungal biofilms: Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the... Agent: Merchant & Gould PC

20080181924 - Culture and use of cells that secrete liver secretory factors: The invention relates to an improved method of culturing hepatocyte cells and non-hepatocyte cells that are capable of secreting liver secretory factors and their use in implantable compositions for treating liver diseases and disorders in patients in need thereof.... Agent: Greenlee Winner And Sullivan P C

20080181926 - Composites and methods of preparation and use thereof: The invention provides composites, methods for their preparation, composites prepared according to the methods, and methods for using the composites.... Agent: Viksnins Harris & Padys Pllp

20080181927 - Device for local and/or regional delivery employing liquid formulations of therapeutic agents: Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention... Agent: Philip S. Johnson Johnson & Johnson

20080181928 - Coatings for implantable medical devices for liposome delivery: Disclosed herein are medical devices, such as implantable medical devices (e.g., stents), comprising at least one coating covering at least a portion of the device comprising dry film. The dry film comprises at least one lipid bilayer and at least one pharmaceutically effective agent. Upon exposure to an aqueous fluid,... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20080181929 - Method for determining optimum intraocular locations for drug delivery implant: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.... Agent: Allergan, Inc.

20080181930 - Punctal plugs and methods of delivering therapeutic agents: The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating... Agent: Alcon

20080181931 - Antimicrobial medical devices including silver nanoparticles: The present invention provides methods for making an antimicrobial medical device, preferably an antimicrobial ophthalmic device, more preferably an antimicrobial extended-wear contact lens, which contains chloride-treated silver nanoparticles distributed uniformly therein. The antimicrobial medical device can exhibit antimicrobial activity over an extended period of time but is substantially free of... Agent: Ciba Vision Corporation Patent Department

20080181932 - Compositions for oral delivery of pharmaceuticals: The invention provides methods and compositions for the oral delivery of pharmaceutically active agents. In particular, the compositions generally comprise a plurality of pharmaceutically active agents embedded in a matrix that is substantially erodable when contacted with an aqueous medium. The compositions may also include an inner core comprising an... Agent: Kv Pharmaceutical Company

20080181933 - Chewing gum compositions of varenicline: A chewing gum composition including a water insoluble base portion; a water soluble portion; and a therapeutically effective amount of varenicline or its pharmaceutical acceptable salt thereof. A method for reducing nicotine addiction and aiding in the cessation or lessening of tobacco use in an individual by administering to an... Agent: Pfizer Inc Steve T. Zelson

20080181934 - Novel enhanced medicinal delivery system processes and products thereby especially useful for children: Pharmacologically effective amounts of a medication are delivered in pleasant tasting delivery vehicles, including gelatins and candies. Mechanisms for the reduction in surface area of noxious taste-imparting aspects of conventional medicines, and dilutive effects of positive masking elements for such medicines, especially products for inducing children to take medicines, are... Agent: Greenberg Traurig LLP (la)

20080181935 - Human placental collagen compositions, and methods of making and using the same: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.... Agent: Jones Day

20080181936 - Hemostatic textile material: A hemostatic textile material to stop bleeding comprising a dialdehyde cellulose (DAC) carrier wherein the degree of oxidation of the dialdehyde cellulose varies from about 1.5% to 12%; and a blood coagulation factor selected from the group consisting of chitosan and gelatin; the blood coagulation factor being chemically immobilized thereon;... Agent: Bachman & Lapointe, P.C.

20080181937 - Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard): Methods and compositions for preventing memory loss and reducing the onset of Alzheimer's disease and the pathological symptoms associated therewith including memory loss, reduced cognitive function and dementia are provided. These methods and compositions comprise dosage regimens that provide for the daily administration of effective amounts of Vitamin C, Vitamin... Agent: Hunton & Williams LLP Intellectual Property Department

20080181938 - Methods and compositions for transdermal delivery of nucleotides: The present invention relates to formulations and related methods for transdermal delivery of nucleic acids. Specifically, the invention relates to a formulation containing lipids and an alcohol and which is capable of providing effective transdermal delivery of nucleic acid. The formulation can be used effectively to deliver nucleic acids for... Agent: Thorpe North & Western, LLP.

20080181939 - Polymersomes and related encapsulating membranes: Provided are methods for preparing and delivering stable, purely synthetic, self-assembling, controlled release, polyethylene oxide (PEO)-based polymersome vesicles, and the resulting PEO-based polymersomes capable of such controlled release, and methods of use therefor for the controlled transport and delivery of encapsulatable, cytotoxic, anticancer active agents contained therein. Further provided are... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20080181940 - Method for accelerating expression of cpt-1: The present invention relates to a composition containing genistein that accelerates the expression of the Carnitine Palmitoyl Transferase-1 (CPT-1) for improving or treating obesity. More particularly, the composition of the present invention comprises genistein that accelerates the expression of the CPT-1, an important enzyme for the lipolysis of fatty acid,... Agent: Sughrue Mion, PLLC

20080181943 - Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use thereof: The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist; and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080181942 - Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis: Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse.... Agent: Davidson, Davidson & Kappel, LLC

20080181941 - Orally administrable opioid formulations having extended duration of effect: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in... Agent: Darby & Darby P.C.

20080181944 - Dosage form comprising therapeutic formulation: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.... Agent: Dewipat Incorporated

20080181945 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Marlin J Messick

20080181946 - Controlled release delivery system for metformin: The invention relates to a controlled release delivery system for Metformin comprising of (a) therapeutically effective amount of Metformin or pharmaceutically acceptable salts there of; (b) hydrophilic polymers and (c) hydrophobic lubricating agent(s). The invention also relates to a method of making the said solid dosage form.... Agent: Nixon & Vanderhye, PC

20080181947 - Controlled release dosage form of tacrolimus: A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080181948 - Solid pharmaceutical dosage formulations: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant,... Agent: Paul D. Yasger Abbott Laboratories

20080181950 - Biofilm-inhibiting medical products: A biofilm-inhibiting medical product includes a carrier formed from a natural, bioremodelable material, whereby the carrier includes a biocidal bismuth thiol agent and/or one or more other biofilm-inhibiting or wound healing agents. A method for using the biofilm-inhibiting medical product to treat a wound or tissue defect in a patient's... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20080181949 - Nanoemulsion vaccines: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and... Agent: Casimir Jones, S.c.

20080181951 - Treatment of humans with colloidal silver composition: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties.... Agent: Stefan Kirchanski

20080181953 - Composition containing a tensioning polymer and hybrid particles, methods of use: Composition containing, in a physiologically acceptable medium, a tensioning polymer and organic-mineral hybrid particles. Process, particularly for facial skin, in particular wrinkled skin, involving the application of the invention composition to the skin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080181952 - Perfusive organ hemostasis: Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080181954 - Chondrocyte therapeutic delivery stystem: Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.... Agent: Nutter Mcclennen & Fish LLP

20080181961 - Amorphous oxcarbazepine and the production thereof: Oxcarbazepine compositions of enhanced bioavailability are described that contain oxcarbazepine with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products include solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising oxcarbazepine, a solubility-enhancing polymer and a single solvent, a solvent... Agent: International Specialty Products William J. Davis, Esq.

20080181960 - Carotenoids of enhanced bioavailability: Carotenoid compositions of enhanced solubility and bioavailability are described that contain at least one carotenoid with at least one solubility-enhancing polymer. In one embodiment, the carotenoid is a provitamin A carotenoid such as β-carotene. In another embodiment the carotenoid is a non-provitamin A carotenoid such as lycopene or lutein. Described... Agent: International Specialty Products William J. Davis, Esq.

20080181963 - Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said... Agent: Buchanan, Ingersoll & Rooney PC

20080181962 - Formulation process method to produce spray dried products: A method for preparing solid materials is described. One aspect of the method includes the steps of (a) providing a feedstock comprising an organic material(s) in a solvent system containing a non-solvent for the organic material at an elevated temperature and/or pressure above ambient conditions, (b) distributing the feedstock into... Agent: International Specialty Products William J. Davis, Esq.

20080181957 - Increased amorphous stability of poorly water soluble drugs by nanosizing: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and... Agent: Philip S. Johnson Johnson & Johnson

20080181958 - Nanoparticle fabrication methods, systems, and materials: Nanosized particles are molded from granules of organic substances in nano-scale molds. The nano-scale molds can be fabricated from non-wetting, low surface energy polymeric materials. The nanosized particles can be virtually any shape, are typically less than 500 micrometers in a broadest dimension, and can include pharmaceutical compositions, biologic drugs,... Agent: Morgan, Lewis & Bockius LLP

20080181955 - Natural dietary supplement and method for enhancing human libido: A dietary supplement includes resveratrol in a therapeutically effective amount to permit release of nitric oxide (NO) during sexual stimulation and at least one polyphenol in a therapeutically effective amount to inhibit formation of type 5 phosphodiesterase (PDE-5). The dietary supplement is a dry powder derived from Muscadine grapes that... Agent: Christopher C. Dremann, P.C.

20080181956 - Oil-in-water personal care composition: A personal care composition in the form of an oil-in-water emulsion is disclosed that provides improves skin feel. The personal care composition comprises from a silicone elastomer; a silicone fluid; a particulate material having a refractive index of less than about 1.8; a polymeric thickener; and water. The personal care... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080181959 - Solid composites of a calcium receptor-active compound: The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith.... Agent: Kenyon & Kenyon LLP

20080181964 - Microparticles: A method of forming particles, comprises accelerating a first stream comprising a first liquid, applying a charging voltage of at most 1.5 kV to the first stream, and vibrating the first stream, to form particles.... Agent: Evan Law Group LLC

20080181965 - Loaded latex optical molecular imaging probes: The present invention relates to a loaded latex particle comprising a latex material made from a mixture represented by formula (X)m-(Y)n-(Z)o-(W)p, wherein Y is at least one monomer with at least two ethylenically unsaturated chemical functionalities; Z is at least one polyethylene glycol macromonomer with an average molecular weight of... Agent: Patent Legal Staff Eastman Kodak Company

20080181966 - Modafinil pharmaceutical compositions: Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.... Agent: Cephalon, Inc.

20080181967 - Placental or umbilical cord tissue compositions: The present invention encompasses compositions, including solutions, gels, and pastes, manufactured from amniotic membrane, umbilical cord membrane, or both. The present invention also encompasses methods of making such compositions, and methods of using the compositions to treat conditions of the eye.... Agent: Jones Day

20080181968 - Pesticide composition: Stable non-toxic pesticide composition having fungicidal and insecticidal properties including a pesticide that is nontoxic to mammals; one or more disinfectants; a vegetable oil; and one or more stabilizing agents. In one example, one or more stabilizing agents are selected and are present in an amount in combination with the... Agent: Downs Rachlin Martin PLLC

20080181969 - Polymer composite: A polymer composite comprising a thermoplastic polymer compounded with a phenolic antioxidant, an organo-disulfide antioxidant, and a silver-based antimicrobial agent. The specified combination of antioxidant stabilizers is superior in inhibiting undesirable discoloration of thermoplastic polymers in the presence of compounded silver-based antimicrobial agents. A process of preparing such a composite,... Agent: Andrew J. Anderson Patent Legal Staff

20080181970 - Combinations of vanadium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080181971 - Combination cancer treatments comprising elsamitrucin and other agents: Disclosed herein are methods relating to combination cancer treatments that include elsamitrucin and other agents.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080181972 - Compositions and methods for maintaining, strengthening, improving, or promoting eye health: Compositions for maintaining, strengthening, improving, or promoting eye health comprise α-lipoic acid, ascorbic acid, and α-tocopherol, or pharmaceutical equivalents thereof. The compositions are useful to prevent, stabilize, reverse and/or treat visual acuity loss in subjects having, or being at risk of developing, an ocular disease. The compositions can further comprise... Agent: Bausch & Lomb Incorporated

20080181973 - Chlorine dioxide gel and associated methods: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid... Agent: Michael N. Haynes

20080181974 - Cosmetic composition containing an amber extract: It further relates to the use of an amber extract as a cosmetic agent acting on the dermal supporting proteins and/or the enzymatic systems that degrade the dermal proteins and/or the glycan-type essential components of the extracellular matrix, particularly proteoglycans, for improving the essential biomechanical properties of the skin, namely... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080181975 - Vasoprotective agent: This invention provides a vasoprotective agent containing a plant or its extract as an effective ingredient. The plant is selected from the group consisting of rosemary, sage, geranium herb, adlai, field horsetail, bitter orange peel, fucus, burdock, dokudami, Japan pepper, Ophiopogon tuber, ginkgo, natsume and dishcloth gourd.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080181976 - Aqueous external preparation for scalp: An aqueous external preparation for scalp, that is directly applied to the scalp to improve the elasticity and luster of newly grown or growing hair without affecting the safety or the feeling of touch of the hair, contains the following components (a) a eucalyptus extract; (b) a blood flow enhancer;... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080175788 - Method of diagnosing, monitoring, staging, imaging and treating prostate cancer: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.... Agent: Jan E Massey Licata Or Kathleen A. Tyrrell Licata & Tyrrell P.c.

20080175789 - Modified psma ligands and uses related thereto: The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA.... Agent: Ropes & Gray LLP

20080175792 - Integrin targeted imaging agents: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for αvβ3 integrin, other than an antibody. The nanoparticles may further include biologically active agents,... Agent: Morrison & Foerster LLP

20080175791 - Assay for anti-metastatic agents: This invention relates, e.g., to a method for identifying an agent that inhibits a metastatic cell (e.g. that inhibits cancer metastasis), comprising measuring the amount of seeding of a tumor by a detectably labeled, metastatic cell, in a subject, in the presence and absence of a putative agent, wherein the... Agent: Venable LLP

20080175790 - Imaging of light scattering tissues with fluorescent contrast agents: A system and method for non-invasive biomedical optical imaging and spectroscopy with low-level light is described. The technique includes a modulated light source coupled to tissue to introduce excitation light. Fluorescent light emitted in response to the excitation light is detected with a sensor. The AC intensity and phase of... Agent: Baker Botts L.l.p.

20080175793 - Urea foam: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to... Agent: Law Offices Of Arthur E. Jackson

20080175796 - Delivery of drug esters through an inhalation route: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a method aspect of the present invention, a drug ester is delivered to a patient through an inhalation route. The method... Agent: Swanson & Bratschun, L.l.c

20080175795 - Novel derivatives of amino acids for treatment of obesity and related disorders: Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels... Agent: Beyer Weaver LLP

20080175794 - Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues: Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080175797 - Preventing airway mucus production by administration of egf-r antagonists: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist... Agent: Bozicevic, Field & Francis LLP

20080175798 - Peptide-based hair protectants: Peptide-based hair protectants, formed by coupling at least one hair-binding peptide with at least one sunscreen agent, are described. The hair-binding peptide portion of the peptide-based hair protectant binds to hair with high affinity, thus keeping the sunscreen agent attached to the hair for long lasting protection. Hair care compositions... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080175799 - Dentifrice compositions comprising as a soluble calcium sequestering agent a derivative comprising a phosphonate group: A dentifrice composition is disclosed comprising a soluble calcium sequestering agent that is not an oxidising agent, wherein the soluble calcium sequestering agent is a polymeric material comprising a phosphonate group. The composition has an RDA value of below 30 and an IVSR value greater than 50 (when compared to... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080175800 - Use of specific menthyl 3-oxocarboxylic acid esters as physiologically active cooling substances: d

20080175801 - Stable peroxide containing personal care compositions: The present invention relates to stable personal care composition, including oral care compositions containing a peroxide source. The compositions are stabilized by eliminating or minimizing the presence in the composition of metals having radical forming potential with the peroxide. Preferably, the metals that are eliminated or reduced are cobalt, copper,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080175803 - Cosmetic compositions, methods of applying said compositions, and methods of making said compositions: A cosmetic composition includes talc or a talc substitute, mica, and iron oxide. The cosmetic composition optionally includes starch, tapioca, and zinc oxide. When applying the cosmetic composition to a user's skin as a body powder or the like, the composition enables the user to control the powder tint.... Agent: Nixon & Vanderhye, Pc

20080175804 - Novel block polymers, compositions comprising them, and treatment methods: c

20080175802 - Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations: Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations, containing ingredients of vegetable origin, in addition to conventional sun filters and excipients.... Agent: Young & Thompson

20080175805 - Cosmetic foundation: The present invention provides a cosmetic mineral foundation, which is a loose powder, comprising Unfermented Green Rooibos Extract (Aspalathus Linearis Leaf), which functions as an antioxidant, and helps reduce the appearance of fine lines and wrinkles, and diminish signs of aging caused by free-radical damage. The foundation is gentle for... Agent: Cislo & Thomas LLP

20080175806 - Cholesteric liquid crystal composition: e

20080175807 - Composition for hair: It is an object of the present invention to provide a composition for hair which comprises highly safe nanoparticles having high transparency due to the small particle size and high permeability into hair and scalp. The present invention provides a composition for hair which comprises protein nanoparticles containing an active... Agent: Sughrue Mion, Pllc

20080175808 - Keratin-enhancing compositions: The invention relates to compositions for keratin materials (hair or eyelashes) such as mascaras, topcoats and basecoats containing at least one tackifier and at least one semi-crystalline alkyl(meth)acrylate.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080175809 - Silicone copolymer and cosmetics comprising the same: wherein R1 is a hydrogen atom or a hydrocarbon group having 1 to 3 carbon atoms, R2 is a hydrocarbon group having 1 to 24 carbon atoms, R3 is a divalent hydrocarbon group having 1 to 4 carbon atoms, R4 is an aliphatic hydrocarbon group having 1 to 6 carbon... Agent: Birch Stewart Kolasch & Birch

20080175810 - Topical compositions for cosmetic and pharmaceutical use: This invention relates to topical compositions in the form of dispersion gels formed by dispersing into an aqueous gel phase a substantially homogenous organic solution containing at least one active ingredient and at least one organic polymer solubilized in an organic carrier. The organic carrier comprises at least one water-miscible... Agent: Jerry Zhang

20080175811 - Method and composition for use in preparation of a patient for surgery: Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080175812 - Polymer coatings containing phytochemical agents and methods for making and using same: This invention relates to compositions comprising a polymer base incorporating antifouling compositions suitable for use in aquaculture, marine and architectural systems as paints, structures or coatings. In particular, the present invention relates to a polymer based coating incorporating a biocidal antifouling composition suitable for use with aquaculture equipment. The present... Agent: Frommer Lawrence & Haug

20080175813 - Novel attractants for vespid wasps: This invention relates to novel methods and compositions, wherein chopped dried apple or apple pomace can be used as supplementary lures for trapping wasps in the family Vespidae in combination with volatile chemical attractants, including (but not limited to) heptyl butyrate, acetic acid and isobutanol. Said vespid wasps may be... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080175815 - Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment or related conditions: The invention relates to methods, commercial packages and compositions for the diagnosis, prognostication and treatment of reproduction-associated diseases. The invention also relates to methods, commercial packages and compositions for the determination and modulation of endometrial receptivity.... Agent: Ogilvy Renault LLP

20080175814 - Quinoline derivatives for modulating dna methylation: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation... Agent: Seed Intellectual Property Law Group Pllc

20080175817 - Biocompatible material composition adaptable to diverse therapeutic indications: A biocompatible material genus serves as the foundation for multiple material composition species, each adapted to a specific therapeutic indication.... Agent: Ryan Kromholz & Manion, S.c.

20080175816 - Maintenance and propagation of mesenchymal stem cells: Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.... Agent: Williams & Anderson Plc

20080175818 - Adenoviral vectors having a protein ix deletion: Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used... Agent: Townsend And Townsend And Crew, LLP

20080175820 - Method for treating diabetic ulcers: A method and means have been developed to deliver a therapeutic dose or dosages of the angiogenic molecule, Vascular Endothelial Growth Factor (VEGF) that results in a statically significant decrease in the time to achieve 100% wound closure and accelerates the rate of healing in experimental diabetic ulcers. Toxicity is... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080175819 - Vector system: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.... Agent: Townsend And Townsend And Crew, LLP

20080175829 - Method for inducing neural differentiation: A method for inducing neural differentiation includes treating a bone marrow stem cell with a neurotrophic factor and/or dibutyryl cAMP (dbcAMP), wherein the neurotrophic factor includes or is glial cell line-derived neurotrophic factor (GDNF) or pituitary adenylate cyclase-activating polypeptide (PACAP).... Agent: Panitch Schwarze Belisario & Nadel LLP

20080175827 - Phospholipase c zeta mediated oocyte activation, compositions for use therein, and assays for detecting and identifying agents for treating male infertility: m

20080175828 - Proliferated cell lines and uses thereof: The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080175824 - Co-culture of placental stem cells and stem cells from a second source: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem... Agent: Jones Day

20080175826 - Methods and systems for extended in vitro culture of neuronal cells: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body.... Agent: Wilson Sonsini Goodrich & Rosati

20080175825 - Mixed cell populations for tissue repair and separation technique for cell processing: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080175821 - Neuronal regeneration material screening method by ex vivo model: The present invention relates to a neuronal regeneration material screening method using ex vivo models, more precisely a neuronal regeneration material screening method using an organotypic spinal cord slice culture. The neuronal regeneration material screening method using spinal cord slices of living bodies of the present invention can be effectively... Agent: Jhk Law

20080175822 - Non-human primate embryonic stem and germ cells: methods of use and methods of making same: e

20080175823 - Use of cytokines and mitogens to inhibit pathological immune responses: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.... Agent: Morgan, Lewis & Bockius, LLP

20080175830 - Culture-expanded t suppressor cells and methods of use thereof: This invention relates to culture-expanded T suppressor cells derived from CD25−CD4+ T cells, and their use in modulating immune responses. This invention provides methods of producing culture-expanded T suppressor cells, which are antigen specific, and their use in modulating autoimmune diseases and transplantation rejection.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080175832 - Materials and methods for prevention and treatment of rna viral diseases: The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080175831 - Neuroprotection by blood flow stabilization: A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age-related macular degeneration (AMD), epilepsy and diabetes, in... Agent: Welsh & Katz, Ltd

20080175833 - Treatment of glycogen storage disease type ii: Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.... Agent: Nixon & Vanderhye, Pc

20080175834 - Carboxypertidase u (cpu) mutants: This invention relates to mutant forms of carboxypeptidase U with increased thermal stability relative to wild-type. In addition to the individual thermal stabilizing mutations identified (at positions 166, 204, 219, 230, 251, 315), the inventors have identified a region (S327-H357) that is crucial to the stability of CPU. The invention... Agent: Astrazeneca R&d Boston

20080175835 - Anti-addl antibodies and uses thereof: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also... Agent: Licata & Tyrrell P.c.

20080175837 - Dpp4 inhibitor and pharmaceutical use thereof: wherein each R1 and R3 represents a hydrogen atom (H) and an L-amino acid residue; R2 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline, alanine... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080175836 - Immunogenic composition based on conditionally live virion and method for producing the same: A conditionally live virion and method for making the same whereby the viral DNA or RNA is modified so that the virion is incapable of replication unless a protein supplement is added to the expression system. The expression system is either a traditional cell culture or cell free expression system... Agent: Williams Mullen

20080175839 - Compositions against cancer antigen liv-1 and uses thereof: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.... Agent: Seattle Genetics, Inc.

20080175840 - Methods for treating angiogenesis related disorders: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.... Agent: The Scripps Research Institute

20080175838 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic... Agent: Townsend And Townsend And Crew, LLP

20080175841 - Antagonistic anti-htnfsf13b human antibodies: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are... Agent: Eli Lilly & Company

20080175842 - Compositions and methods for treatment: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of... Agent: Merchant & Gould Pc

20080175844 - Alk1 receptor and ligand antagonist and uses thereof: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates... Agent: Wolf Greenfield & Sacks, P.c.

20080175843 - Novel polypeptides, dnas encoding the same and use thereof: Polypeptide produced from human stromal cell line, the process for the preparation of the polypeptide, DNA encoding the polypeptide, vector carrying the DNA, host cell transformed by the vector, antibody of the polypeptide, and pharmaceutical composition containing the polypeptide or the antibody.... Agent: Sughrue-265550

20080175846 - Antibodies against cancer antigen tmeff2 and uses thereof: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080175845 - Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist: The present invention provides methods for treating inflammatory arthritis in an individual, comprising administering to the individual an effective amount of AAV (rAAV) vector comprising a polynucleotide encoding a pro-inflammatory cytokine antagonist, wherein the individual is being treated systemically with a polypeptide pro-inflammatory antagonist but still has one or more... Agent: Morrison & Foerster LLP

20080175847 - Anti-dll4 antibodies and methods using same: The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20080175848 - Methods for treating conditions associated with the accumulation of excess extracellular matrix: The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular... Agent: Mandel & Adriano

20080175849 - Immunoreactive peptides from epstein-barr virus: Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.... Agent: Woodcock Washburn LLP

20080175850 - Methods for human allografting: A method of preparing a human recipient for a graft from a human which includes: administering donor peripheral blood progenitor cells to the recipient, and providing a minimally ablative.... Agent: Fish & Richardson Pc

20080175851 - Methods and compositions for enhancing the growth of fish and shellfish: Methods and compositions for enhancing weight gain and/or feed efficiency in fish and shellfish are disclosed. The methods include administering an agent, such as an antibody, which reduces the bioavailability in fish or shellfish of a prostaglandin or leukotriene lipid precursor. The methods also include administering an antibody which enhances... Agent: Foley & Lardner LLP

20080175852 - Synthesis of phosphocholine ester derivatives and conjugates thereof: Aspects of the present invention include methods of synthesizing phosphocholine analogues and the phosphocholine conjugates formed therefrom and their use in preventing infections caused by microorganisms.... Agent: Woodcock Washburn LLP

20080175853 - Virus-like particles for the induction of autoantibodies: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the... Agent: Knobbe, Martens, Olson & Bear, LLP

20080175854 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Patrick J. Halloran

20080175855 - Peptide useful in immunomodulation: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to... Agent: Winston & Strawn LLP Patent Department

20080175856 - Enterococcus antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.... Agent: Fulbright & Jaworski L.l.p.

20080175857 - Streptococcus pneumoniae proteins and nucleic acid molecules: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.... Agent: Hunton & Williams LLP Intellectual Property Department

20080175858 - Method of preparing a seaweed degradation product and a composition for preparing a seaweed degradation product: A method to prepare seaweed degradation product comprising contacting a bacterium having 16S rRNA sequence consisting of the nucleic acid sequence as recited in SEQ ID NO: 1 with a seaweed is provided.... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20080175859 - Recombinant infectious laryngotracheitis virus and uses thereof: m

20080175860 - Canine vaccines: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by... Agent: Pharmacia & Upjohn

20080175861 - Modified polymerases and attenuated viruses and methods of use thereof: The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed.... Agent: Akerman Senterfitt

20080175862 - Recombinant flavivirus vaccines: The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.... Agent: Clark & Elbing LLP

20080175863 - Methods and compositions for increasing replication capacity of an influenza virus: In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides... Agent: Johnathan Klein-evans

20080175864 - Treating hepatitis c virus infection: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HVC release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.... Agent: Richard Aron Osman

20080175865 - Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias: The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising Lactobacillus strains in an inactivated form and carriers and/or excipients commonly used in vaccine preparations.... Agent: The Firm Of Hueschen And Sage

20080175866 - Identification of genes: e

20080175867 - P. gingivalis antigenic composition: The present invention provides an antigenic composition, the composition comprising at least one recombinant protein. The recombinant protein comprises at least one epitope. The epitope is reactive with an antibody which is reactive with a polypeptide having the sequence set out in SEQ. ID. NO. 3 or SEQ. ID. NO.... Agent: Morrison & Foerster LLP

20080175868 - Vaccine: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of... Agent: Seed Intellectual Property Law Group Pllc

20080175869 - Mycobacterial sulfation pathway proteins and methods of use thereof: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or... Agent: Bozicevic, Field & Francis LLP

20080175870 - Human cancer stem cells: This invention discloses isolated populations of human cancer stem cells. Methods for characterizing, isolating and culturing human cancer stem cells are also disclosed. Uses for human cancer stem cells are provided.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080175871 - Eliciting improved immune responses: An improved immune response is achieved in an animal by administering, for example injecting, a cocktail of peptides that are similar to, but different from, a target peptide against which it is desired to create antibodies. The similar peptides preferably have the same peptide sequence as the target peptide, but... Agent: Wilmerhale/new York

20080175872 - Controlled release dosage form containing lercanidipine and a performance-enhancing acid: A controlled release dosage form containing lercanidipine, or a salt thereof, a performance-enhancing acid, and at least one other pharmaceutical excipient exhibits enhanced in vitro dissolution of lercanidipine, enhanced storage stability based upon the reduced degradation of lercanidipine, and/or enhanced in vivo bioavailability of lercanidipine as compared to an otherwise... Agent: Innovar, Llc

20080175873 - Modified release composition of at least one form of venlafaxine: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080175877 - Adhesives with antiperspirant and/or anti-inflammatory additives: Embodiments of the present invention provide adhesives comprising additives, such as anti-inflammatory and antiperspirant additives, to address various problems a user may encounter when contacting the adhesive or wearing a bandage or other device/substrate using such an adhesive.... Agent: Schwabe, Williamson & Wyatt, P.c. Pacwest Center, Suite 1900

20080175874 - Applied care compositions comprising functionalized nano-particles: A composition comprising: (a) at least one cationic, functionalized nano-particle; and (b) an applied care composition. Additionally, a composition comprising: (a) at least one anionic, functionalized nano-particle; and (b) an applied care composition.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080175875 - Cosmetic compositions: This invention relates to cosmetic compositions containing aqueous nanodispersions of polyurethane ionomers based on polytrimethylene ether glycol (“PO3G”), and an active cosmetic ingredient. In a particularly preferred embodiment, the PO3G is derived predominantly from monomers obtained from renewable resources, making the personal care products of this embodiment of the present... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080175876 - Novel chitinase and uses thereof: Disclosed herein are novel chitinase polypeptides and nucleic acids encoding the polypeptides. Also disclosed are related vectors, host cells, compositions, and uses.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080175878 - Protease for activating clotting factor vii: A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080175879 - Table cloths or table covers invisible to and capable of repelling insects and animals: There is provided a covering for laying over the top of any eating, drinking or sleeping surface, or a table cloth or a table cover substantially less visible, if not invisible to, and capable of, repelling insects and animals. The covering is opaque and bears a color that is outside... Agent: Panagiota Betty Tufariello, Esq. The Law Offices Of P.b Tufariello, P.c.

20080175881 - Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents: According to an aspect of the present invention, implantable or insertable blood-contacting devices are provided, which contain one or more release regions that release nitric oxide and one or more anti-restenotic agents. The release region contains one or more polymeric components. The release region also optionally contains one or more... Agent: Mayer & Williams Pc

20080175884 - Medical devices containing rapamycin analogs: A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such... Agent: Squire, Sanders & Dempsey L.l.p.

20080175882 - Polymers of aliphatic thioester: A coating comprising a polymer that comprises units derived from an aliphatic thioester on a medical device is provided.... Agent: Squire, Sanders & Dempsey LLP

20080175880 - Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis: The present invention provides method of treating and preventing vascular inflammation, atherosclerosis, restenosis, plaque destabilization and bypass graft failure comprising the administration of a therapeutically effective amount of pyridoxal-5′-phosphate or a pharmaceutically acceptable salt thereof. The present invention further provides an intravascular stent for use with a narrowed artery having... Agent: Leydig Voit & Mayer, Ltd

20080175883 - Self-assembling peptide amphiphiles: The present invention provides for self-assembling peptide amphiphiles that are capable of forming nanofibers. In particular, the present invention provides for diacetylene peptide amphiphiles that find use as scaffolds for tissue growth or for drug delivery.... Agent: Casimir Jones, S.c.

20080175886 - Blends of poly(ester amide) polymers: Provided herein is a bioabsorbable implantable device comprising a bioactive agent and a poly(ester amide) (PEA) polymer blend.... Agent: Squire, Sanders & Dempsey LLP

20080175885 - Porous, degradable implant made by powder molding: The exemplary embodiment of the present invention are provided which relate to at least partially degradable implants and methods for the manufacture thereof which can use powder molding techniques. For example, a suspension can be provided comprising a plurality of first particles of at least one organic polymer, a plurality... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080175887 - Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs: Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080175888 - Combination therapy comprising actinidia and steroids and uses thereof: Disclosed is a combination of an Actinidia preparation and one or more steroids, and the use of such a combination to prevent and/or treat allergic and non-allergic inflammatory conditions or diseases, to alleviate at least one symptom of such conditions or diseases, and/or to regulate an immune response in a... Agent: Sheridan Ross Pc

20080175889 - Method and composition for coating wounds and protecting skin using a polyether polyurethane solution: A solution of polyether polyurethane resin dissolved in a solvent system containing 2-methyloxolane (2-MeOX) solvent and at least one volatile co-solvent. The solution may also contain a functional amount of solubilized adhesive agent. Upon drying, the resulting protective elastic film has good adhesion to human and other animal skin. The... Agent: Wesley B. Ames

20080175890 - Transdermal delivery systems: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form... Agent: Thomas P. Mccracken Durect Corporation

20080175891 - Methods, compositions, and formulations for preventing or reducing adverse effects in a patient: The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a... Agent: Wilson Sonsini Goodrich & Rosati

20080175893 - Gas-containing liposomes: The present invention provides gas-containing liposomes. In particular, the present invention provide methods of generating gas-containing liposomes where the gas is introduced under pressure, as well as gas-containing liposomes which contain a large volume of gas (e.g., 10 ul of gas per 5 mg of gas-containing liposomes). In certain embodiments,... Agent: Casimir Jones, S.c.

20080175894 - Methods of treating neurological conditions with hematopeitic growth factors: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080175892 - Nanostructure-drug conjugates: Nanostructure-drug conjugates and associated methods of use are provided. In one embodiment, a nanostructure-drug conjugate comprising a Cn, a crosslinker, and a drug is provided, wherein Cn refers to a fullerene moiety or nanotube comprising n carbon atoms. A method of treating cancer is also provided, comprising administering a therapeutically... Agent: Baker Botts, LLP

20080175895 - System, devices, and methods for iontophoretic delivery of compositions including antioxidants encapsulated in liposomes: Systems, devices, and methods for delivering one or more active ingredients to intradermal tissues, deep regions of pores, and intradermal tissues in the vicinity of the pores. In some embodiments, a composition is provided including a plurality of liposomes including a cationic lipid, and an amphiphilic glycerophospholipid having a saturated... Agent: Seed Intellectual Property Law Group Pllc

20080175896 - Tweak-pseudomonas exotoxin a fusion protein for cancer therapy: Soluble TNF superfamily ligand monomers, including TWEAK, spontaneously associate into a homotrimeric structure that binds with high affinity to a cell surface receptor(s). A TWEAK is fused with a modified (mutant) Pseudomonas exotoxin (PE38). This fusion protein's TWEAK domain binds with high affinity to a fibroblast growth factor-inducible 14 (Fn14)... Agent: Whiteford, Taylor & Preston, LLP Attn: Gregory M Stone

20080175897 - Dosage forms for administering combinations of drugs: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption... Agent: Law Office Of Michael A. Sanzo, Llc

20080175898 - Oral drug capsule component incorporating a communication device: An improved upper capsule portion (62) of an oral drug delivery capsule (60) that includes an upper capsule portion (62) and a lower cup shaped capsule portion (64), the lower cup shaped capsule portion (64) containing a medical formulation (66), the lower capsule portion (64) being made of a material... Agent: Butzel Long Ip Docketing Dept

20080175899 - Formulation for promoting sinus health in nasal cavities: A formulation for promoting sinus health includes at least one probiotic agent in combination with N-acetyl cysteine (NAC) and a bioflavonoid or derivative thereof.... Agent: Jaeckle Fleischmann & Mugel, LLP

20080175900 - Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20080175902 - Methods for slowing the progression of multiple sclerosis: Methods are provided herein for slowing the progression of multiple sclerosis comprising administering a therapeutically effective amount of a cannabinoid to a patient suffering from MS.... Agent: Davidson, Davidson & Kappel, Llc

20080175901 - Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to pharmaceutical formulations of a crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20080175903 - Treatment of anxiety with eszopiclone: The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.... Agent: Peter F. Corless

20080175905 - Estrogen/serm and estrogen/progestin bi-layer tablets: The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation.... Agent: Wilmerhale/wyeth

20080175907 - Oral insulin therapies and protocol: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired... Agent: Pearl Cohen Zedek Latzer, LLP

20080175906 - Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof: The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080175904 - Particulate comprising a calcium-containing compound and a sugar alcohol: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure... Agent: Edwards Angell Palmer & Dodge LLP

20080175908 - Tablet-in-tablet compositions: The present invention is directed to tablet-in-tablet compositions comprising one or more estrogens in a first layer and a therapeutic agent in a second layer, and processes for their preparation... Agent: Wilmerhale/wyeth

20080175909 - Delivery device containing venlafaxine and memantine and method of use thereof: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined... Agent: Innovar, Llc

20080175910 - Pharmaceutical dosage forms for controlled release producing at least a timed pulse: The present invention relates to delayed release coated cores comprising an active substance in their core and a polymer coating comprising at least one or more ammonio methacrylate copolymer, characterized in that the core comprises at least a surfactant; to monolithic or multiparticulate pharmaceutical dosage forms comprising such delayed release... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080175911 - Compositions and methods for soft tissue repair: Methods and compositions for treating soft tissue defects are provided. The composition, which is injectable directly into the tissue adjacent to the defect, comprises a fibrosis inducing factor in a carrier. The method includes preparing the composition comprising a fibrosis inducing factor in a carrier and delivering the composition into... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080175915 - Microparticles: A method of forming particles comprises accelerating a stream comprising a liquid; and vibrating the stream, to form particles. The particle may have a diameter that is smaller than the diameter of the nozzle used to form the stream, allowing for the formation of micro- and nano-sized particle.... Agent: Evan Law Group Llc

20080175912 - Polyoxyalkylene-alkyl functional siloxane resins and aqueous compositions thereof: Siloxane resins containing both polyoxyalkylene M siloxy units and alkyl functional M and T siloxy units and aqueous compositions thereof are disclosed. The aqueous compositions contain dispersed particles stabilized by the siloxane resin, and are useful for the entrapment and delivery of various personal, household, and medical care actives.... Agent: Alan Zombeck Dow Corning Corporation

20080175914 - Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors: The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a... Agent: Glaxosmithkline

20080175916 - Vessel enlargement by arteriogenic factor delivery: A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.... Agent: Blakely Sokoloff Taylor & Zafman LLP

20080175913 - Wood preservative compositions comprising isothiazolone-pyrethroids: The present invention relates to wood preservative compositions comprising an effective amount of a pyrethroid compound in combination with an isothiazolone compound, methods and processes for preserving wood using the wood preservative compositions of the invention, and wood comprising the wood preservative compositions of the invention.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080175918 - Chemically cross-linked elastomeric microcapsules: The present invention relates to the fields of stably encapsulating oral care, skin care, scented, flavoring agents for cued release, and therapeutic agents for extended and sustained release. The invention relates to the stable microencapsulation of these agents for incorporation into dentifrices, topical ointments, microwavable food products, dryer sheets and... Agent: Baker Botts L.l.p.

20080175917 - Microparticles containing a h+,k+-atp-ase inhibitor: A method for the preparation of homogenous microparticles containing a H+, K+-ATP-ase inhibitor using a fluid-bed granulation technique. The microparticles that have a desired size distribution are selected. At least 80% of the microparticle based on its dry weight content is the acid labile H+, K+-ATP-ase inhibitor.... Agent: White & Case LLP Patent Department

20080175919 - Urea compositions with cooling effect: The present invention includes a urea powder, the particles of which are encapsulated in a dimethicone and silica network, prior to being incorporated into anhydrous compositions. The encapsulated urea is capable of imparting a cooling activity to a topical composition. The invention also pertains to topical, cooling compositions containing an... Agent: Peter Giancana

20080175920 - Polymer capsule and process for the preparation thereof: Provided are a polymer capsule having a diameter of 10 to 1,000 nm which is prepared by the copolymerization of a hydroxycucurbituril compound with an organic compound having at least two thiol groups, and a method of preparing the same.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080175921 - Colloidal formulation of long-acting insulin and its preparation: o

20080175922 - Ophthalmic gallium compositions and methods of their use: Provided are ophthalmic pharmaceutical compositions comprising gallium. These compositions are designed primarily for topical ocular and intraocular administration. Also provided are methods of use for the compositions in the treatment of human and veterinary diseases and disorders. Treatable diseases and disorders include adverse conditions of the eye and adnexal tissues... Agent: Lawrence R. Bernstein

20080175923 - Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3): This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen synthase kinase 3 activity.... Agent: Fish & Richardson P.c.

20080175924 - System and method for diagnosis of neuropsychiatric disorders: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone... Agent: Bond, Schoeneck & King, Pllc

20080175925 - Method and composition for the treatment of herpes virus: A composition and method for oral application to mouth tissue to reduce the symptoms of herpes simplex virus infection, said composition comprising an anti-viral agent, an antioxidant agent, an analgesic agent and a flavorant.... Agent: Christina Ezell

20080175927 - Method for preventing plant diseases: The present invention relates to a composition for preventing at least one plant disease resulted from infection of plant pathogens and a method for preparing the same. Particularly, the composition contains extract of at least one plant selected from the group consisting of Coptis chinensis Franch., Phellodendron genus plant, Sanguinaria... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20080175926 - Process for treating storage reservoirs contaminated with mycotoxins: The present invention relates to a process for treating, by means of eugenol or clove oil, reservoirs for storing cereals, oil-producing plants, dry fruit or dry vegetables contaminated with mycotoxins.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080175928 - Compositions for juice-based moisturizers: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080175929 - Analytical methods for identifying ginseng varieties: An analytical method for identifying woods-grown ginseng and mountain cultivated ginseng comprise: (a) preparing ginseng extracts, (b) acquiring fingerprint regions by GC-MS analysis, (c) selecting at least 8 GC peaks for similarity calculation; (d) calculating similarity coefficients; and (e) comparing similarity coefficients of samples to those of standards.... Agent: Matthias Scholl

20080175930 - Water dispersible compositions and methods of using the water dispersible compositions: Described herein are compositions comprising a nematicide intermixed with lecithin and a co-surfactant that form stable dispersions in water. Also disclosed are methods of controlling nematodes in soil by application of such compositions.... Agent: Archer Daniels Midland Company

20080175931 - Cosmetic foundation: The present invention provides a cosmetic mineral foundation, which is a pressed powder, comprising unfermented green rooibos extract (aspalathus linearis leaf), which functions as an antioxidant, and helps reduce the appearance of fine lines and wrinkles, and diminish signs of aging caused by free-radical damage. The foundation is gentle for... Agent: Cislo & Thomas LLP

20080175932 - Method for decreasing nicotine and other substance use in humans: A method for decreasing nicotine and other substance use in humans is disclosed. Tetrahydroberberine (THB) and its analogs, l-Tetrahydropalmatine (l-THP) and l-Stepholidine (l-SPD), are present in and can be isolated from several plants in the Magnoliidae superorder. According to the disclosed method, THB and its analogs are used to block... Agent: Quarles & Brady LLP

20080175933 - Horse liniment: The horse liniment is a veterinary composition for topical application for the relief of muscle and joint pain in horses. The composition contains, by weight, about 49% alcohol, 20% olive oil, 10% arnica, 14% creosote, 1% iodine, 2% turpentine, 2% camphor, and 2% alum. The ingredients may be mixed at... Agent: Litman Law Offices, Ltd.

20080175934 - Novel herbal composition of extracts of quercus infectoria, process for preparing the same and use thereof: Disclosed is a novel herbal composition comprising extract of Quercus infectoria having rich and effective concentration of as antioxidants and phenolic compounds. Further the present invention provides a process for preparing said composition and use thereof in cosmeceuticals, pharmaceuticals and health drinks for treating oxidative stress and other life style... Agent: Darby & Darby P.c.

20080175935 - Method to treat skin conditions with narcissus tazetta bulb extract: Methods for the prevention or treatment of disorders and complications of disorders resulting from cell damage caused by an aging-related isoform of NADH oxidase (arNOX) are described. The agent for such inhibition comprises processed various Narcissus tazetta extracts, preferably IBR-DORMIN® Narcissus tazetta bulb extract, both alone and in combination with... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080170988 - Method of preparing nanoparticles of alginate-galactosyl-polylsine: The technological plan of preparing approach of galactosized algin-polylysine nanoparticle is: synthesize galactosized polylysine by hydrogenization of amine, to apply “finished gelatin of Wharton” to synthesize galactosized algin-polylysine nano gelatin of Wharton: dissolve algin and Calcium chloride in the water respectively, with the magnetic agitation of algin solution, add Calcium... Agent: Knobbe Martens Olson & Bear LLP

20080170989 - Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may... Agent: Immunomedics, Inc.

20080170990 - Methods for myocardial imaging in patients having a history of pulmonary disease: The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A2A adenosine receptor agonists to a mammal undergoing myocardial imaging and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080170992 - Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins: The present application is directed to radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).... Agent: Siemens Corporation Intellectual Property Department

20080170991 - Selectively targeted antimicrobial peptides and the use thereof: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or... Agent: Perkins Coie LLP

20080170993 - Thymidine analogs for imaging: The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of... Agent: Millen, White, Zelano & Branigan, P.C.

20080170994 - Macromolecular compositions that cross the blood-brain barrier and methods of use thereof: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's... Agent: Wilson Sonsini Goodrich & Rosati

20080170995 - Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Dickstein Shapiro LLP

20080170996 - Compositions and methods for stimulation of lung innate immunity: Embodiments of the invention include compositions, formulations and methods for the enhancement of a subject's biological defenses against infection, for example the subject's innate immunity against infection. Aspects of the invention provide a rapid and temporal enhancement or augmentation of biological defenses against microbial infection.... Agent: Fulbright & Jaworski L.L.P.

20080170997 - Compositions for the treatment and prevention of cancer: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as... Agent: Christie, Parker & Hale, LLP

20080170998 - Method and composition for treating or prevending an oral cavity: The invention relates to a composition for treating or preventing an oral cavity by preventing adhesion of Porphyromonas gingivalis as periodontopathic bacterium to oral tissue. The invention also relates to a composition for treating or preventing an oral cavity containing a peptide in which arginine and histidine bind alternately. Preferably,... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20080170999 - Thienopyrimidines as cooling agents: Use of a compound of formula (I) where R1 is a C4-6 alkylene linkage optionally substituted by a C1-4alkyl group; R2 is ═NH, —NH2 or —OH; R3 is C1-5 alkyl optionally terminated by a hydroxy, phenyl or a 5- or 6-membered heterocyclic group such as furyl or N-imidazolyl and R4... Agent: Unilever Patent Group

20080171001 - Mineralization toothpaste: The present invention is directed to a tooth cleaning and mineralizing composition including an abrasive composition in an amount sufficient to provide the tooth cleaning and mineralizing composition with a relative dental abrasion of from 100 to 250; and a stabilized tooth mineralizing mineral composition.... Agent: Philip S. Johnson Johnson & Johnson

20080171000 - Tooth mineralization compositions: The present invention is directed to a tooth surface mineralizing composition including a stabilized tooth mineralizing mineral composition containing calcium and phosphate and a dissociable source of a mineral that provides a mineral ionic species selected from calcium and phosphate upon dissociation.... Agent: Philip S. Johnson Johnson & Johnson

20080171005 - Composition for making-up the skin comprising at least one resin, at least one block copolymer and at least one solid fatty substance, free from volatile oil: e

20080171003 - Process of preparing jambu extract, use of said extract, cosmetic compositions comprising thereof and cosmetic products comprising said cosmetic compositions: The present invention discloses a process of preparing jambu extract that results in a jambu extract free from chlorophyll and derivatives of this compound. It is a method for isolating the components of interest in a simplified way, with quite high process yield, higher than 85%. The present invention further... Agent: Alston & Bird LLP

20080171002 - Products for receptor mediated activation and maturation of monocyte-derived dendritic cells by a phosphorylated glucomannane polysaccharide: Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.... Agent: Lathrop & Gage Lc

20080171004 - Uv protection: The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for... Agent: Millen, White, Zelano & Branigan, P.C.

20080171008 - Composition containing a polyorganosiloxane polymer, a tackifier, a wax and a block copolymer: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising (a) at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080171006 - Cosmetic composition containing a block copolymer, a tackifier, a silsesquioxane wax and/or resin: The present invention is directed to a method of making up keratinous substrates involving applying onto the keratinous substrate a composition containing a) a block copolymer, b) a tackifier, c) an alkyl silsesquioxane wax, d) a liquid fatty phase, and e) optionally, a colorant.... Agent: L'oreal Usa/ Patent Department

20080171007 - Cosmetic compositions containing a block copolymer, a tackifier and a high viscosity ester: A method of making up keratinous substrates involving applying onto the keratinous substrates a composition containing a) a block copolymer, b) a tackifier, c) a wax, d) a liquid fatty phase, e) a high viscosity ester, and f) optionally, a colorant.... Agent: L'oreal Usa/ Patent Department

20080171010 - Use of a polysiloxane/polyurea block copolymer for the treatment of keratinous fibers: The present disclosure relates to a treatment of the hair, which is resistant to shampooing operations, wherein the individual hairs are coated with a cosmetic composition comprising a polysiloxane/polyurea block copolymer wherein at least one volatile nonsilicone organic solvent and at least one silicone compound exhibit a viscosity of less... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171009 - Keratin fibre makeup kit: e

20080171011 - Compositions for juice-based skin cleansers: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080171012 - Fouling resistant coatings and methods of making same: The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.... Agent: Northwestern University C/o Quarles & Brady LLP

20080171013 - Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.... Agent: Lucas & Mercanti, LLP

20080171015 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080171016 - Death domain containing receptors: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080171014 - Interleukin-13 binding proteins: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding... Agent: Abbott Bioresearch

20080171017 - Use of cd25 antibodies in immunotherapy: A method for the treatment of proliferative disease or infectious disease, comprising administering to the patient an effective amount of a CD25 binding molecule.... Agent: Novartis Corporate Intellectual Property

20080171018 - Serotype of adenovirus and uses thereof: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins... Agent: Trask Britt

20080171026 - Compositions and methods for elimination of unwanted cells: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium... Agent: Fish & Richardson P.C.

20080171027 - Compositions and methods for elimination of unwanted cells: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium... Agent: Fish & Richardson P.C.

20080171025 - Highly branched hk peptides as effective carriers of sirna: The present invention is directed to methods of transfecting cells with siRNA, by contacting a transfection complex with one or more cells, where the transfection complex includes a transport polymer and siRNA. The transport polymer may include for example, H3K8b and/or structurally similar compounds. The invention is also directed to... Agent: Castellano PLLC

20080171028 - Use of compounds involved in biosynthesis of nucleic acids to increase yield of bacterial cultures: Microbial starter cultures. More specifically, a method for preparing a microbial starter culture wherein the microorganism is inoculated in a culture medium comprising at least one 5 yield enhancing agent selected from the group consisting of a purine base, a pyrimidine base, a nucleoside and a nucleotide. Such microbial starter... Agent: Foley And Lardner LLP Suite 500

20080171019 - Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use: The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages, that are isolated, processed and cryopreserved, and the therapeutic uses of such stem and progenitor cells upon application. Such compositions may be useful for... Agent: Dr. Rashida A. Karmali

20080171020 - Method and composition for repairing epithelial and other cells and tissue: The present invention is directed to the expansion, preferably TVEMF-expansion, of mammalian blood adult stem cells, wherein the expansion takes place in a rotating bioreactor, preferably a TVEMF-bioreactor, to compositions resulting from the expanded cells, and to a method of treating an epithelial cell/tissue related disease or condition or repairing... Agent: Ladas & Parry LLP

20080171023 - Method to increase class i presentation of exogenous antigens by human dendritic cells: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a... Agent: Townsend And Townsend And Crew, LLP

20080171022 - Methods and composition for complementing treatments to eradicate neoplastic cells: Methods and systems are provided to facilitate treatment for a neoplastic disease include providing information of stem cells that can be isolated from an individual prior to diagnosis with a neoplastic disease; processing and storing the stem cells, such as cord blood or bone marrow stem cells, in a format... Agent: Fish & Associates, PC Robert D. Fish

20080171021 - Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation: The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.... Agent: Fish & Richardson PC

20080171024 - Prevention of biofilm formation using pegylated blood products: A method for preventing bacterial biofilm formation in a blood product, the method comprising modifying a blood product with a polymer selected from the group consisting of polyethylene glycol (PEG), PEG derivatives and mixtures thereof. Preventing bacterial biofilm formation in this way increases the planktonic to adherent ratio of any... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080171029 - Beauty mask: A beauty mask uses natural material, like coconut milk, royal jelly, vegetable enzymes, aloe and loofah, for achieving a whitening, anti-wrinkle and moisturizing effect without further additives, thereby avoiding skin injuries, and which can be stored for a long time; furthermore a method for packing and storing beauty masks, by... Agent: Pro-techtor International Services

20080171030 - Compositions for juice-based moisturizers: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080171031 - Compositions for juice-based moisturizers: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080171032 - Dietary supplement composition and method of use for the treatment and prevention of oxidative stress: Described are compositions comprising a combination of superoxide dismutase and at least one member selected from the group consisting of astaxanthin, tocotrienol, carnosine, and benfotiamine, and methods of using the same for ameliorating or preventing the detrimental effects of oxidative stress.... Agent: Mccarter & English LLP Cityplace I

20080171033 - Compositions and methods for treating diseases associated with angiogenesis and inflammation: Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or... Agent: Wang Law Firm, Inc.

20080171034 - Compounds and methods for cytoprotection: a

20080171035 - Mammalian cell membrane proteins; related reagents: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.... Agent: Dnax Research Inc. Legal Department

20080171040 - Antibody-drug conjugates and methods: where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other... Agent: Genentech, Inc.

20080171037 - Apo-3 ligand polypeptide: A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided. Nucleic acid molecules encoding Apo-3 Ligand, chimeric molecules and antibodies to Apo-3 Ligand are also provided.... Agent: Genentech, Inc.

20080171039 - Compositions against cancer antigen liv-1 and uses thereof: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.... Agent: Seattle Genetics, Inc.

20080171038 - Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of Idiopathic Thrombocytopenia Purpura (ITP). Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has ITP and pharmaceutical compositions comprising such antagonists.... Agent: Townsend And Townsend And Crew, LLP

20080171036 - Taci antibodies and uses thereof: TACI receptor antibodies are provided. The TACI antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the TACI antibodies are also provided.... Agent: Clark & Elbing LLP

20080171041 - Method for treating inflammation: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema,... Agent: Zymogenetics, Inc. Intellectual Property Department

20080171043 - Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding... Agent: Morrison & Foerster LLP

20080171042 - Cd44 variants as therapeutic targets: The present invention involves diagnostic and treatment methods for prostate cancer. We have shown that prostate cancer cells overexpress variant isoforms of CD44 (CD44v7-10). Overexpression is observed at the messenger RNA and protein levels. The present invention includes using diagnostic procedures such as RT-PCR and in situ hybridization to distinguish... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080171045 - Compositions and methods for diagnosing and treating cancer: An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080171044 - Compositions and methods for inhibiting squamous cell carcinoma: The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 5 alpha 3 G4-G5 domain.... Agent: Bozicevic, Field & Francis LLP

20080171048 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080171047 - Methods of treating graft versus host disease: The present invention relates to methods for treating or preventing graft versus host disease (GVHD) in a host subject, with the methods comprising treating either the graft or the host subject or both to reduce the interaction of graft-origin, CD103-expressing cells with cells in the host. The present invention also... Agent: Sughrue Mion, PLLC

20080171046 - Novel proteins and nucleic acids encoding same: Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo, PC

20080171049 - Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof: The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be... Agent: Morrison & Foerster LLP

20080171050 - Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists: A method is provided for treating a mammal with hyperproliferative disease stimulated by a ligand of epidermal growth factor receptor. The method includes administering an effective amount of an antagonist of a member of the EGF family of receptors. The method also includes administering an EGFR antagonist in combination with... Agent: Lucas & Mercanti, LLP

20080171051 - Cancer treatment: The invention relates to methods and compositions for treatment of cancer. In one embodiment the method involves the use of a c-FLIP inhibitor as the sole active agent. In another embodiment the invention relates to the treatment of p53 mutant cancers using combinations of c-FLIP inhibitors and chemotherapeutic agents.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080171052 - Hmgb1 protein inhibitorsand/or antagonists for the treatment of vascular diseases: The use of HMG box-binding molecules and molecules having sequence homology with HMG box for the preparation of therapeutic agents for the treatment of vascular diseases is described... Agent: Young & Thompson

20080171053 - Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof: A number of immunologically active agents are described, including an isolated protein or polypeptide that includes the amino acid sequence of SEQ ID NO: 1, immunogenic conjugates containing either the protein or polypeptide, a full-length Pneumocystis kexin, or a full length Streptococcus pneumoniae pneumococcal surface protein A (PspA), antibodies recognizing... Agent: Nixon Peabody LLP - Patent Group

20080171054 - Treatment of micro-organism infection: The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections.... Agent: Fish & Richardson PC

20080171055 - Methods for diagnosing and treating cns disorders by trans-blood-brain barrier delivery of protein compositions: The invention provides methods for treating or diagnosing CNS disorders by systemic administration of therapeutic or diagnostic protein compositions that are capable of crossing the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to remain substantially intact. The agents are transported across... Agent: Wilson Sonsini Goodrich & Rosati

20080171056 - Use of cd23 antagonists for the treatment of neoplastic disorders: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080171057 - Reagents, devices, and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research: The invention describes methods for proteomic analysis involving the mapping of samples in N-dimensional shape space. The applications include the classification of samples on the basis of the three-dimensional shapes of substances they contain. A panel of P (>>1) reagents, with P≧N, called X(j), with j=1 to P, is used,... Agent: Vermette & Co.

20080171058 - Compositions and methods for synergistic induction of antitumor immunity: The present invention discloses a synergistic effect between vaccines encoding tumor-associated antigen and vaccines encoding tumor endothelial marker (8) (TEM8). Potent antitumor immunity was generated by the combined use of these vaccines. Tumor supported by vasculature and for which a tumor-associated antigen has been defined can be treated with this... Agent: Benjamin Aaron Adler Adler & Associates

20080171059 - Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens: Methods for eliciting in an animal in need thereof a cell-mediated immune response specific to an antigen, the method comprising providing an antigen preparation comprising particles on the surface of which the antigen is attached, and administering the antigen preparation to the animal, wherein the particles are taken up by... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20080171060 - Modulation of immune response and methods based thereon: The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived... Agent: Jones Day

20080171061 - Human endogenous retrovirus polypeptide compositions and methods of use thereof: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide.... Agent: Bozicevic, Field & Francis LLP

20080171062 - Recombinant hbsag virus-like particles containing polyepitopes of interest, their production and use: The hepatitis B surface antigen (HBsAg) can assemble into sub-virion virus like particles (VLPs). By fusing immunogenic peptides to the amino-terminus of HBsAg, several bivalent vaccines have been developed. In one example, an optimized HIV-1 polyepitope-HBsAg recombinant protein assembled into VLPs and was efficiently secreted. DNA immunization in mice resulted... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171063 - Novel composition: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080171064 - Live attenuated salmonella for use as vaccine: The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a... Agent: Duane Morris, LLPIPDepartment

20080171065 - Methods of treating nerve entrapment syndromes: Methods of treating nerve entrapment syndromes and/or the pain associated with nerve entrapment syndromes using botulinum type B toxin are disclosed. These methods involve, for example, injections of botulinum type B toxin to the tissue impinging on the nerve and/or the interstitial area around the nerve and/or the connective tissue... Agent: Wilson Sonsini Goodrich & Rosati

20080171066 - Listeriolysin-containing bacillus spores as antigen delivery agents: The present invention is based on the provision of non-pathogenic Bacillus spores comprising: (i) a polynucleotide sequence encoding a phagosome membrane-rupturing agent; and (ii) a polynucleotide sequence encoding at least one further heterologous polypeptide. These may be used to deliver heterologous polypeptides to cells and in particular to phagocytic cells.... Agent: Nixon & Vanderhye, PC

20080171067 - Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may... Agent: Immunomedics, Inc.

20080171068 - Antimicrobial, infection-control and odor-control film and film composite: A novel method of producing an odor-controlling textile is disclosed. More specifically, a textile structure is disclosed that contains thin breathable film layer having an activatable antimicrobial odor controlling material. Most specifically, the present invention relates to a textile composite that is composed of a flexible breathable film layer with... Agent: Barlow, Josephs & Holmes, Ltd.

20080171069 - Parasiticidal aqueous suspension: Parasiticidal aqueous suspension Parasiticidal aqueous suspension typically comprising from 1 to 15% by weight of silica and from 30 to 45% of alkali metal bicarbonate, and method for controlling the development of parasites on animals reared in buildings, according to which the animal's environment in the building is brought into... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080171071 - Novel igf-1 composition and its use: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity... Agent: Novartis Vaccines And Diagnostics Inc.

20080171070 - Polyelectrolyte multilayer film, preparation and uses thereof: The invention relates to polyelectrolyte multilayer films presenting a tunable biological activity and methods for preparing the same. The invention further relates to surfaces presenting such films and uses thereof, such as for the controlled delivery of biologically active agents.... Agent: Nixon & Vanderhye, PC

20080171072 - Ocular inserts containing apomorphine: A gelatin-based insert was designed to deliver apomorphine by the ocular route. A clinical trial showed the product to have an efficacy similar to intravenously-administered apomorphine with a better safety profile in terms of adverse effects.... Agent: Ade & Company Inc.

20080171073 - Antibiotic-sensitive lactic acid bacteria strains: Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This may present a risk of a horizontal transfer of functional antibiotic genes. The present invention relates to a method of obtaining novel tetracycline-sensitive strains of the genus of Bifidobacteriacea (Bifidobacterium sp.). In particular, the present... Agent: Foley And Lardner LLP Suite 500

20080171074 - Hemostatic composition, apparatus, and methods: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties.... Agent: Patent Group Chocate Hall & Stewart

20080171075 - Neuropathy cream: The present invention provides compositions for transdermal pain relief. According to one embodiment, a transdermal composition for the relief of pain in a subject comprising: amitriptyline, clonidine, ketamine and an anti-inflammatory in a base having at least ten percent (10%) lecithin isopropyl palmitate oil (lipoil).... Agent: Meredith & Keyhani, PLLC

20080171076 - Dermatological and/or cosmetic composition containing polypeptides: The present invention relates to the use of proteins of the UCP family, or UCP protein polypeptide or peptide fragments, as an active agent, alone or in association with at least one other active agent, in or for the preparation of a pharmaceutical and/or dermatological and/or cosmetic composition. The invention... Agent: Young & Thompson

20080171077 - Method and apparatus for making uniformly sized particles: A method and apparatus for making substantially uniformly sized liposomes and other small particles are provided. Droplets of a first liquid are ejected into a laminar flow of a second liquid, each droplet having a volume of from 0.97V to 1.03V, where V is the mean droplet volume and 1... Agent: Christie, Parker & Hale, LLP

20080171080 - Methods of treating neurological conditions with hematopoeitic growth factors: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080171081 - Pharmaceutically acceptable phosphate-glycerol carrying bodies: This invention relates to three-dimensional synthetic and semi-synthetic compositions having biological activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly it relates to preparations and uses of synthetic and semi-synthetic bodies, such as liposomes, which after introduction into the body... Agent: Foley & Lardner LLP

20080171082 - Pharmaceutically acceptable phosphate-glycerol carrying bodies: This invention relates to three-dimensional synthetic and semi-synthetic compositions having biological activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly it relates to preparations and uses of synthetic and semi-synthetic bodies, such as liposomes, which after introduction into the body... Agent: Foley & Lardner LLP

20080171078 - Uniformly sized liposomes: Compositions suitable for use as site-specific biological vectors are provided and comprise substantially uniformly sized liposomes having very narrow size distributions. In particular, the compositions comprise a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from... Agent: Christie, Parker & Hale, LLP

20080171079 - Vaccine: Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080171083 - Pharmaceutical compositions comprising an amphiphilic starch: The present invention relates to controlled or sustained release solid pharmaceutical compositions, to pharmaceutical excipients for use in the manufacture of such compositions and to methods of producing such compositions and excipients. The controlled or sustained release excipients include a release controlling excipient comprising an amphiphilic starch.... Agent: Davidson, Davidson & Kappel, LLC

20080171084 - Pharmaceutical semi-sold composition of isotretinoin: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle... Agent: Dickinson Wright PLLC

20080171085 - Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration: A novel biphasic pharmaceutial or nutraceutical composition delivers both an immediate and a sustained dose of a pharmaceutical or nutraceutical agent in the same unit dose. An oral unit dose of melatonin includes melatonin in a sustained-release matrix contained in a solid phase, such as a tablet of capsule, and... Agent: Gabor L. Szekeres

20080171086 - Solid dosage forms of valsartan and amlo dipine and method of making the same: Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.... Agent: Novartis Corporate Intellectual Property

20080171087 - Methods and materials for increasing the adhesion of elution control matrices to substrates: The present invention relates to methods and components for increasing adhesion of an elution control matrix to a polymeric substrate, and medical devices including such components. In an embodiment, the invention includes a medical device including a substrate having a surface, the substrate comprising a polysiloxane, a parylene layer contacting... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20080171088 - Nanoparticulate megestrol formulations: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080171089 - Stable anti-nausea oral spray formulations and methods: Stable formulations of selective 5-hydroxytryptamine receptor antagonists for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration are provided. A preferred embodiment includes ondansetron in a concentration of about 5.1 to about 5.2% w/w; propylene glycol in a concentration of about 60.1 to... Agent: Dickstein Shapiro LLP

20080171090 - Method of producing coated fine particles: An object of the present invention is to provide a method for easily producing coated fine particles in which core fine particles are coated with a coating layer component, etc. There are provided a method of producing coated fine particles comprising core fine particles coated with a coating layer component,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080171091 - Nanoparticulate compositions of immunosuppressive agents: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080171092 - Graft prosthesis, materials and methods: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080171093 - Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms: The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods... Agent: Fulbright & Jaworski L.L.P.

20080171094 - Treatment of burns: The invention relates to the treatment of burn injuries. Described are methods for modulating a burn injury in a subject, the method comprising providing the subject with a gene-regulatory peptide or functional analogue thereof. Also described is the use of an NF-kappaB down-regulating peptide or functional analogue thereof for the... Agent: Trask Britt

20080171095 - Carnosine-related compounds for preventing and treating impaired neurovascular blood flow: The present invention discloses a dipeptide that is useful for the prevention or treatment of impaired neurovascular blood flow. The invention teaches that administration of carnosine-related compounds reduce focal ischemia (i.e., for example, stroke) symptomology whether administered before, or after, the impaired blood flow.... Agent: Peter G. Carroll Medlen & Carroll, LLP

20080171096 - Method for decreasing nicotine and other substance use in humans: A method for decreasing nicotine and other substance use in humans is disclosed. Tetrahydroberberine (THB) and its analogs, l-Tetrahydropalmatine (l-THP) and l-Stepholidine (l-SPD), are present in and can be isolated from several plants in the Magnoliidae superorder. According to the disclosed method, THB and its analogs are used to block... Agent: Quarles & Brady LLP

20080171097 - Product liquorice root and oak bark in combination with dexapanthenol: The invention relates to a pharmaceutical composition and the use of same for treating diseases that are caused by microorganisms, and as a cosmetic. In one embodiment, the pharmaceutical composition comprises an extract of liquorice root and oak bark in combination with dexpanthenol.... Agent: Morris Manning Martin LLP

20080166292 - Pharmaceutical dosing method: Systems, devices, and methods for more accurately determining a radiopharmaceutical dose administered to a patient by relying on a time factor. Particularly, broadly contemplated herein is the administration of a dose on the basis of an elapsed time from when a dose was last accurately measured in the past to... Agent: Gregory L Bradley Medrad Inc

20080166293 - Receptor-mediated uptake of peptides that bind the human transferrin receptor: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080166295 - Antibodies, polypeptides and uses thereof: Provided are methods of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. Also provided are antibodies that have the amino acid sequences i) to iii), iv) to vi), or i) to... Agent: Wolf Greenfield & Sacks, P.C.

20080166294 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20080166296 - Pharmaceutical gallium compositions and methods: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation... Agent: Diehl Servilla LLC

20080166297 - Radionuclide-chitosan complex having an improved stablilized gelatin in administering them to the body and their preparation method: The present invention relates to a radionuclide-chitosan complex solution and its preparation method, and more particularly to the radionuclide-chitosan complex solution having a viscosity of 300˜2,400 cps, comprising an aqueous chitosan solution or a freeze-dried chitosan labeled with a radionuclide. The radionuclide-chitosan complex solution according to the present invention has... Agent: Lucas & Mercanti, LLP

20080166298 - 6- (2, 3, 4, 5-tetrahydro-1h-benzo [d] azepin-7-yloxy) -nicotamide derivatives as radio labelled ligands: The present invention relates to radiolabelled compounds of formula (I), which are useful for the labelling and diagnostic imaging of histamine H3 receptor functionality.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080166299 - Acetylene derivatives and their use for binding and imaging amyloid plaques: The invention relates to radiolabeled compounds and their use in methods of imaging amyloid deposits, as well as to methods of their manufacture. The invention also relates to compounds for inhibiting the aggregation of amyloid proteins that form amyloid deposits, methods for delivering therapeutic agents to amyloid deposits, as well... Agent: Woodcock Washburn LLP

20080166300 - Cancer associated protein phospatases and their uses: Detection of expression of the provided phosphatases in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and for determining patient prognosis. The encoded polypeptides further provide a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further... Agent: Bozicevic, Field & Francis LLP

20080166301 - Steroidal antiestrogens and antiandrogens and uses thereof: The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorder. In an aspect of the invention, such treatments include therapeutic compositions comprising... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080166302 - Substance emitting product: The present invention relates to a substance emitting product comprising a combustible structural element incorporated with a pesticide and/or fragrance wherein the combustible structural element is a coil shaped cardboard strip characterized in that the combustible structural element is a made from palm fibres. The palm fibres are obtained from... Agent: Birch Stewart Kolasch & Birch

20080166303 - Colored or colorable foamable composition and foam: There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the... Agent: Wilmerhale/boston

20080166305 - Aerosol compositions containing fluorine substituted olefins and methods and systems using same: Various compositions, including particularly aerosol compositions containing fluorinated olefins, including particularly 2,3,3,3-tetraluorpropene (HFO-1234yf), in a variety of applications are disclosed.... Agent: Honeywell International Inc.

20080166304 - Inactivation of microorganisms with multidrug resistance inhibitors and phenothiaziniums: The present invention relates to the use of phenothiaziniums and microbial MDR inhibitors to inactivate microorganisms. Methods of the present invention are useful in the treatment of living subjects and in the decontamination of inanimate objects and substances.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080166306 - Composition for mucosally delivering fruit cell cultures and/or preparations derived therefrom and methods of using same: A novel pharmaceutical composition formulated for mucosal delivery for the treatment of inflammatory disorders is disclosed and methods of generating same.... Agent: Nath & Associates

20080166307 - Oral care compositions comprising a hippophae extract: Oral care compositions that comprise a Hippophae extract, as well as methods for reducing inflammation, inhibiting gingivitis, improving oral hygiene and maintaining or increasing systemic health of a mammal, are disclosed.... Agent: Colgate-palmolive Company

20080166308 - Tanning method: The present invention relates to a method for tanning the human body and in particular for avoiding application edges during tanning, which is characterised in that at least one formulation comprising 0.1 to 1% by weight of at least one self-tanning agent substance is applied repeatedly, but at least once... Agent: Millen, White, Zelano & Branigan, P.C.

20080166309 - Composition containing a polyorganosiloxane polymer, a thickening agent and at least one volatile alcohol: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising (a) at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080166310 - Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof: A regime or regimen for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for preventing and/or limiting the depigmentation and/or bleaching and/or for preventing and/or limiting the canities thereof, more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the... Agent: Buchanan, Ingersoll & Rooney PC

20080166311 - Use of agglomerated hydroxyethylcellulose in pharmaceutical, personal care and household care applications: The present invention is related to the use of glyoxal-free compositions, more particularly, to the use of hydroxyethylcellulose agglomerated with low molecular weight hydroxyethylcellulose in consumer products, in particular, pharmaceutical, personal care (excluding oral care compositions), as well as household care applications.... Agent: Hercules Incorporated Hercules Plaza

20080166312 - Compositions for juice-based peels and masks: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080166313 - Compositions for juice-based skin cleansers: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080166314 - Compositions for juice-based treatment serums: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080166315 - Use of compounds for the preservation of the human or animal body and compositions comprising same: e

20080166316 - Composition for hands: A composition for use on the skin includes a carbomer, a starch, vitamins, moisturizers, an astringent, a Pluronic, dimethicone, and an aluminum compound. The composition may further include water, glycerin, emulsifiers, and surfactants. The composition provides therapeutic, conditioning, and other benefits to the skin, particularly when used on the hands,... Agent: Keely Schneiter, P.C.

20080166317 - Modified polyamines: wherein X represents a bond or a —(CR4R5)n— group; Z represents a —CONH—, —(CH2)m—O—, or —(CH2)o—CH(OH)—(CH2)p—(O)q— group; m represents a number 1 to 6; o represents a number 0 to 6; p represents a number 1 to 6; q represents a number 0 or 1; r represents a number 0... Agent: Connolly Bove Lodge & Hutz, LLP

20080166318 - Methods and therapeutic combinations for the treatment of demyelination: The present invention provides methods for treating demyelination and associated conditions by administering at least one sterol absorption inhibitor and compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one demyelination treatment which can be useful for preventing or treating demyelination and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080166319 - Recombinant interferon alpha2 (ifnalpha2) mutants and methods of use thereof: The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.... Agent: Winston & Strawn LLP Patent Department

20080166320 - Geldanamycin-producing strains, uses thereof and methods of producing same: A use of an inoculum of a geldanamycin-producing strain able to survive in a plant rhizosphere as a biocontrol of common scab affecting the plant and a method for biocontrolling common scab comprising the use of such strain. A biologically pure culture of a Streptomyces strain deposited at the American... Agent: Goudreau Gage Dubuc

20080166321 - Method for identification of virulence determinants: Disclosed are methods for the determination of virulence determinants in bacteria and in particular bacteria of the genus Mycobacterium. Also disclosed are compositions and methods for stimulating an immune response in an animal using bacteria and virulence determinants identified by the methods of the present invention.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080166330 - Bacterial compositions for prevention or treatment of atherosclerotic disorders: This invention relates to the treatment of atherosclerotic conditions through the inhibition of lipid oxidising abzymes by altering the composition of the intestinal microbial flora, for example by administering a bacterial composition to the individual. Suitable bacterial compositions may comprise, for example enteric bacteria such as lactobacilli spp, bifidobacteria spp,... Agent: Nixon & Vanderhye, PC

20080166331 - Anti-allergy lactic acid bacteria: The invention described relates to novel strains of lactic acid bacteria and their use in anti-allergy. The composition may be in the form of foodstuffs or in the form of pharmaceutical compositions.... Agent: Joe Mckinney Muncy

20080166322 - Methods for producing an adenovirus type 5 gene transfer vector: pZerotgCMV, an Ad-5-based expression vector in current use for gene transfer stimulates lipogenic enzymes within HepG2 cells (human hepatic carcinoma cells) and primary rat hepatocytes in vitro. Evidence indicates increased lipid accumulation in infected cells compared to uninfected cells. Therefore, inactivation of the E4 ORF1 gene or E4 gene cluster... Agent: Townsend And Townsend And Crew, LLP

20080166323 - Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hermorrhagic shock: Disclosed herein are compositions and methods for preserving cell, tissue, or organ transplants and cultures by increasing the concentration of an intracellular metabolite of the hexosamine biosynthetic pathway. Also described herein are methods of reducing pathogenic effects in a subject by increasing the concentration of an intracellular metabolite of the... Agent: Needle & Rosenberg, P.C.

20080166328 - In vitro expansion of postpartum-derived cells using microcarriers: Compositions and methods for the growth and expansion of mammalian cells in culture are provided. In particular, methods for the growth and expansion of postpartum-derived cells in vitro are provided using surfaces such as microcarrier beads.... Agent: Woodcock Washburn LLP

20080166329 - Medical device and methods for living cell injection: A novel method, using a thermoreversible MC/PBS/Collagen hydrogel coated on the TCPS dish, for harvesting a living cell sheet or spheroid with ECM. In one application, the obtained living cell sheet/spheroid is administered to a joint adapted for implantation and for cartilage regeneration. In another application, the living cell sheet/spheroid... Agent: Hosheng Tu

20080166326 - Method for activating natural killer cells by tumor cell preparation in vitro: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.... Agent: Frommer Lawrence & Haug

20080166327 - Method for amplification of endothelial progenitor cell in vitro: The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080166325 - Method of extensive culture of antigen-specific cytotoxic t cells: The present invention provides methods for inducing, maintaining and expanding CTL (cytotoxic T cell) having an antigen-specific cytotoxic activity at a high level, which is useful in the adoptive immunotherapy, by using as an effective ingredient at least one compound selected from the group consisting of acidic polysaccharides, acidic oligosaccharides,... Agent: Birch Stewart Kolasch & Birch

20080166332 - Methods of treatment of amyloidosis using subsituted ethanolcyclicamine aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080166333 - Bi-stable quantum wire array of self-assembled nanomedicine and the preparation method therefor: ABSTRACT A bi-stable quantum wire array of self-assembled nano-medicine and its process present in the invention. The bi-stable quantum wire array with quantum bit and kondo effect is prepared by self-assembling an oxygen radical antagonist of antioxidase, a β-receptor agonist, a P2 receptor agonist, a calcium antagonist of phenyl alkyl... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080166334 - Combination enzyme for cystic fibrosis: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule,... Agent: Kristina M. Grasso

20080166335 - Slimming cosmetic composition comprising a metalloproteinase as an active agent: The invention relates to a slimming cosmetic composition comprising, by way of an active agent, at least one inhibitor of metalloproteinases −2 and/or −9 or a plant extract containing said metalloproteinase inhibitor. The invention also relates to the use of an inhibitor of metalloproteinases −2 and/or −9 or a plant... Agent: David R Preston & Associates Apc

20080166324 - Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use: The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma... Agent: Townsend And Townsend And Crew, LLP

20080166336 - Cd137 agonists to treat patients with ige-mediated conditions: There are disclosed methods for treating conditions mediated by IgE, comprising administering a CD137 agonist to a mammal afflicted with such a condition. CD137 agonists include CD137 ligand (CD137L) and agonistic antibodies to CD137; mammals to be treated include humans. Conditions mediated by IgE include asthma, atopic dermatitis, and allergy.... Agent: Immunex Corporation Law Department

20080166338 - Il-21 as a regulator of immunoglobin production: A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of... Agent: Leydig, Voit & Mayer, Ltd.

20080166339 - Inhibition of osteopontin for treatment of relapsing autoimmune disease: Methods are provided for the inhibition or prevention of relapses in pre-existing autoimmune disease by decreasing activity or expression of osteopontin in immune cells found in tissues affected by the autoimmune disease. Osteopontin is shown herein to mediate autoimmune relapses and induce a shift to the secondary or progressive stage... Agent: Bozicevic, Field & Francis LLP

20080166337 - Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof: The present invention provides a transmembrane serine protease TADG-12 protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and... Agent: Benjamin Aaron Adler, Ph.d.,j.d. Adler & Associates

20080166341 - Cripto blocking antibodies and uses thereof: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies... Agent: Lahive & Cockfield, LLP

20080166343 - High affinity antibody antagonists of interleukin-13 receptor alpha 1: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody... Agent: Licata & Tyrrell P.C.

20080166340 - Identification of tumour-associated cell surface antigens for diagnosis and therapy: According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumour-associated manner and... Agent: Olson & Cepuritis, Ltd.

20080166342 - Internalizing anti-cd74 antibodies and methods of use: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which... Agent: Immunomedics, Inc.

20080166346 - Lyophilised preparation comprising antibodies against the efg receptor: The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080166345 - Medicaments comprising gene recombinant antibody against ganglioside gd3: An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone,... Agent: Nixon & Vanderhye, PC

20080166344 - Method of treating cancer by co-administration of anticancer agents: The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination... Agent: Sughrue Mion, PLLC

20080166347 - Human antibodies specific for interleukin 15 (il-15): Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing... Agent: Lahive & Cockfield, LLP

20080166348 - Uses and compositions for treatment of rheumatoid arthritis: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for... Agent: Lahive & Cockfield, LLP

20080166350 - Genetic products differentially expressed in tumors and the use thereof: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides... Agent: Keown & Zucchero, LLP

20080166349 - Method to inhibit the propagation of an undesired cell population: Disclosed is a method for inhibiting the propagation of an undesired cell population, the method comprising introducing into a cell an antagonist of SGT, or of a functional variant thereof, said antagonist depleting SGT, a functional variant thereof, in a cell of said cell population, and verifying the reduced proliferation... Agent: Foley And Lardner LLP Suite 500

20080166351 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20080166352 - Human anti-b7rp1 neutralizing antibodies: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080166353 - Methods of modulating cd200 receptors: Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor, Also provided are methods of treatment and diagnosis of immune disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080166355 - Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.... Agent: Wilson Sonsini Goodrich & Rosati

20080166354 - Suppression of inhibitors: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080166356 - Pharmaceutical compositions and methods of using secreted frizzled related protein: Pharmaceutical compositions and methods of use in regulation of mammalian bone forming activities of sFRPs (secreted frizzled-related proteins) are disclosed. sFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes like tissue polarity, embryonic development, and tumorigenesis. A sFRP was... Agent: Wyeth C/o Darby & Darby, P.C.

20080166357 - Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6): The invention provides a human DPP6 which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, muscle skeleton diseases, neurological diseases, urological diseases, reproduction disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or... Agent: Banner & Witcoff, Ltd.

20080166359 - Methods of using mek inhibitors: The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.... Agent: Patent Dept Exelixis, Inc.

20080166358 - Quinazoline derivatives and methods of treatment: This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.... Agent: Edwards Angell Palmer & Dodge LLP

20080166360 - Cloning and sequencing of the allergen dac g 5 of dactylis glomerata pollen, its preparation and use thereof: A purified nucleic acid molecule comprising a nucleotide sequence coding for allergen Dac g 5 having amino acid sequence SEQ ID NO. 2, a derivative or a fragment thereof.... Agent: Ip Group Of Dla Piper US LLP

20080166363 - Camptothecin-binding moiety conjugates: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.... Agent: Immunomedics, Inc.

20080166361 - Neutron capture therapy: The present invention relates to immunoconjugates for use in neutron capture therapy, in particular Boron neutron capture therapy, for killing target cells such as tumours. The immunoconjugate of the invention comprises a monoclonal antibody having an affinity of at least 1011 l/mol and a cross-reactivity of less than 10%, and... Agent: Choate, Hall & Stewart LLP

20080166362 - New effector conjugates, process for their production and their pharmaceutical use: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recognition units. The pharmaceutical use of the conjugates for treating proliferative... Agent: Millen, White, Zelano & Branigan, P.C.

20080166364 - Anti-angiogenic compounds: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.... Agent: Fulbright And Jaworski LLP

20080166365 - Composition for adjusting water quality for adminstration of water sanitizer sensitive medicaments or vaccines: A composition for adjusting water quality for administration of water sanitizer sensitive medicaments or vaccines comprising a natural reducing agent, a buffer, and a coloring agent; and a method of delivering a live vaccine through such drinking water or water for spray administration to an animal.... Agent: Intervet Inc. Patent Department

20080166366 - Intracellular delivery vehicles: The invention provides methods and compositions relating to intracellular delivering of agents to eukaryotic cells. The compositions include microbial delivery vehicles such as nonvirulent bacteria comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent. The... Agent: Richard Aron Osman

20080166367 - Custom vectors for treating and preventing pancreatic cancer: The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).... Agent: Leydig, Voit & Mayer, Ltd.

20080166368 - Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at... Agent: Fulbright & Jaworski L.L.P.

20080166369 - Cancer vaccine preparation: A preparation combining a complex of a cancer antigen and a hydrophobized polysaccharide with an agent, e.g., an extract from hemolytic streptococcus, which binds to a Toll-like receptor to stimulate the antigen presenting cells activates all of the antigen presenting cells, the killer T cells and the helper T cells... Agent: Burr & Brown

20080166370 - Immunogenic compositions comprising multiple gonococcal antigens: N. gonorrhoeae is a bacterial pathogen which causes diseases including gonorrhoea, urethritis, cervicitis and pelvic inflammatory disease. In addition, like other inflammatory SYDs, infection is believed to enhance HIV transmission. Within the many proteins of the gonococcal *enome, six have been found to be particularly suitable for immunisation purposes, particularly',... Agent: Novartis Vaccines And Diagnostics Inc.

20080166371 - Optimized expression of hpv 31 l1 in yeast: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for... Agent: Merck And Co., Inc

20080166372 - Live attenuated rotavirus vaccine for oral administration: This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate, wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080166373 - Methods and compositions for delivery and expression of interferon-alpha nucleic acids: The present invention is directed to compositions and methods for the delivery of interferon polypeptides. The invention provides recombinant viral and non-viral vectors for the selective expression of interferon polypeptides in particular cell or tissue types. The invention further provides pharmaceutically acceptable formulations of such vectors for administration to mammalian... Agent: Townsend And Townsend And Crew, LLP

20080166374 - Nucleic acid cancer immunotherapy: A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an... Agent: Akerman Senterfitt

20080166375 - Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells: The present invention provides compositions and methods for inhibiting abnormal cell growth. In particular, the invention provides nucleic acids encoding Diphtheria toxin fusion proteins comprising residues 1-388 of Diphtheria toxin, wherein the native furin cleavage site has been substituted for a matrix metalloproteinase or plasminogen activator cleavage site, and a... Agent: Townsend And Townsend And Crew, LLP

20080166376 - Immunization against chlamydia infection: The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a Mgp002 polypeptide of... Agent: Patrick J Halloran

20080166377 - Human hookworm vaccine: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080166378 - Death receptor sensitizing compounds and methods of use therefor: Methods of identifying death receptor sensitizing compounds and methods of using death receptor sensitizing compounds are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080166379 - Tumor cell vaccines: An effective cancer cell vaccine for canines has been developed. The vaccine is prepared from autologous lymphoma cells transfected with emm55. Once an animal is vaccinated, the expressed Emm55 antigen stimulates an immunogenic response to the tumor cells resulting in significantly increased survival, strong autologous and cross reactive humoral and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080166380 - Method for altering morphology of block copolymer: The invention provides a pharmaceutical formulation comprising drug-encapsulated polymer micelles formed from a block copolymer having a hydrophilic segment and hydrophobic segment, and has been subjected to high-pressure treatment. The invention also provides a treatment method for a block copolymer having a hydrophilic segment and a hydrophobic segment for formation... Agent: Christie, Parker & Hale, LLP

20080166382 - Amphiphilic block copolymers and nanoparticles comprising the same: An amphiphilic block copolymer is disclosed. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nanoparticle and carrier including the amphiphilic block copolymer for delivery of water insoluble drugs, growth factors, genes, or water... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20080166381 - Emulsifier composition based on pentaerythritol esters and aloxylated nonionic emulsifiers: An emulsifier composition including an ester selected from the group consisting of: pentaerythritol, dipentaerythritol, tripentaerythritol, and mixtures thereof; at least one alkoxylated nonionic emulsifier; and less than 10% by weight water, where partial glycerides may be present in an amount of less than 10% by weight, based on the amount... Agent: Cognis Corporation Patent Department

20080166383 - Antiallergic latex or pvc products and the method of making thereof: The present invention provides an antiallergic latex or PVC product, which includes one or more natural antiallergic medicines selected from baicalin, matrine, liquorice saponin, tea polyphenol, arctigenin, oleanolic acid, tetrandrine, sodium ferulate, total alkaloid of asiatic moonseed rhizome, extraction of cortex dictamni radics, ginkgo bilobal A, total glycoside of Rhizoma... Agent: Knobbe Martens Olson & Bear LLP

20080166384 - Stethoscope head cover and associated method: A stethoscope head cover configured to envelop a head of a stethoscope includes a cover member with a cavity therein. The cover member includes first and second openings. The first opening has a size sufficient to slidably engage a cord associated with the head of the stethoscope, and the second... Agent: Thorpe North & Western, LLP.

20080166385 - Method for producing hydrocolloid foams: A method for producing foams, such as sponges, from hydrocolloids is described. A solid or semi-solid gel is formed by dissolving polymeric material in an aqueous solvent. The gel formed is allowed to set, and may optionally then be cut into the desired shape. The gel may be frozen to... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080166386 - Methods of use of biodegradable injectable implants: This invention is directed to the field of medical implants, and more specifically to biodegradable injectable implants and their methods of manufacture and use. The injectable implants disclosed herein comprise glycolic acid and bio-compatible/bio-absorbable polymeric particles containing a polymer of lactic acid. The particles are small enough to be injected... Agent: Vinson & Elkins, L.L.P.

20080166387 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080166388 - Beta-peptides with antifungal activity: The present invention is directed to the design, synthesis and use of various β-peptides exhibiting antifungal activity. The β-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.... Agent: Quarles & Brady LLP

20080166390 - Biodegradable polyphosphazenes containing pyrrolidone side groups: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080166389 - Compositions and methods for treatment of hyperplasia: In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically... Agent: Morrison & Foerster LLP

20080166391 - Zero-order prolonged release coaxial implants: A coaxial implant has been developed using entirely biodegradable polymeric materials. As referred to herein, a coaxial implant is a device having a core containing drug, surrounded by a semi-permeable membrane that controls the rate of release of material from the core. The device is formed by extrusion, using a... Agent: Thomas P. Mccracken Durect Corporation

20080166392 - Positive modulator of bone morphogenic protein-2: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone... Agent: Peacock Myers, P.C.

20080166393 - Eye medication delivery system: An eye medication delivery system for treating an infected eye having a cornea and a conjunctiva, where the medication delivery system comprises a liquid medication applied directly to a surface of a contact lens and placing the contact lens onto the eye such that the liquid medication and the contact... Agent: Nelson Mullins Riley & Scarborough, LLP

20080166395 - Article for delivering substrates to the oral cavity: The present invention is an oral dissolvable pouch with a substrate, for providing therapy and a method of providing therapy using the pouch of the present invention.... Agent: Robert M. Schwartz, P.A.

20080166394 - Food composition for binding acetaldehyde in the mouth and in digestive track and method for preparation of the composition: The object of the invention comprises food compositions, to which one or more acetaldehyde-binding compounds are added. The purpose of the compositions is to reduce the amount of detrimental acetaldehyde in the area of the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through... Agent: Sughrue-265550

20080166396 - Boronate medicaments suitable for short duration anticoagulation: An oral dosage form of a compound selected from boronic acids which have a neutral thrombin (P1) domain linked to a hydrophobic moiety capable of binding to the thrombin (S2) and (S3) subsites, and salts, prodrugs and prodrug salts of such acids, the dosage form comprising a solid phase formulation... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080166397 - Pain-sensitive therapeutic wound dressing: The invention provides a wound dressing comprising a therapeutic agent and a matrix comprising polymers joined by cross-linkages which cross-linkages comprise oligopeptidic sequences which are cleavable by a kallikrein associated with wound fluid such that the rate of release of the therapeutic agent increases in the presence of elevated kallikrein... Agent: Philip S. Johnson Johnson & Johnson

20080166398 - Antifungal compositions: Pharmaceutical compositions useful for treating dermal diseases caused by fungi and yeasts with inflammation and/or associated with a bacterial infection. Such compositions contain a therapeutically effective amount of sertaconazole, or a pharmaceutically acceptable salt, solvate, isomer thereof or mixtures thereof; and a therapeutically effective amount of at least one compound... Agent: Birch Stewart Kolasch & Birch

20080166399 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20080166403 - Long circulating liposome: The present invention relates to a liposome having a phospholipid bilayer and a hydrophilic core, wherein the phospholipid bilayer contains D-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS). The liposomes are first prepared by solvent injection and extrusion method, and then drug loading by ammonium sulfate gradient. The TPGS in the... Agent: Bacon & Thomas, PLLC

20080166402 - Medical compositions for intravesical treatment of bladder cancer: Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080166400 - Pharmaceutically acceptable phosphate-glycerol carrying bodies: This invention relates to three-dimensional synthetic and semi-synthetic compositions having biological activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly it relates to preparations and uses of synthetic and semi-synthetic bodies, such as liposomes, which after introduction into the body... Agent: Foley & Lardner LLP

20080166401 - Use of therapeutically effective lipids and method for producing organ-/tissue-specific therapeutically effective lipids: The use of therapeutically active lipids for organ/tissue-specific enrichment for the treatment of inflammatory, ischemic or degenerative disorders and/or for stimulating a regeneration is arranged and developed such that the lipids are bound on application to carrier molecules for which cell-specific uptake systems in the cells of the organs and/or... Agent: Alston & Bird LLP

20080166404 - Bioadhesive drug formulations for oral transmucosal delivery: Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.... Agent: Weaver, Austin, Villenuve & Sampson LLP Attn: Acelrx

20080166405 - Abuse-resistant oral dosage forms and method of use thereof: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the... Agent: Kenyon & Kenyon LLP

20080166406 - Rapidly disintegrating dosage form comprising magnesium carbonate heavy: A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is found to be an excellent dispersant under basic and neutral conditions,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080166407 - Solid oral formulations for combination therapy: Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a combination of a gastric acid-reducing agent, such as omeprazole and ranitidine, and at least one analgesic/anti-inflammatory agent, such as acetaminophen, naproxen sodium, ibuprofen, tolmetin, and... Agent: Leigh P. Gregory

20080166408 - Oral dosage form comprising rosiglitazone: An oral dosage form, such as a bilayer tablet, comprising a first layer of a first composition and a second layer of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof, (‘the drug’) and a pharmaceutically acceptable carrier therefor, wherein the first and... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080166409 - Shape-retentive hydrogel particle aggregates and their uses: The present invention is related to hydrogel particles and aggregates formed therefrom having characteristics including, without limitation, shape-retentiveness, elasticity, controllable pore sizes and controllable degradation rates that render them useful for a wide variety of applications including, without limitation, the controlled release of biologically active substances, in vivo medical devices,... Agent: Foley & Lardner LLP

20080166410 - Acidic superabsorbent hydrogels: The present invention relates to novel hydrophilic swellable addition polymers comprising improved odor control, a process for their preparation and their use for absorbing aqueous fluids and a process for screening superabsorbents.... Agent: Marshall, Gerstein & Borun LLP

20080166411 - Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles: Pharmaceutical formulations comprising: a compound of low water solubility, having a maximum average particle size; a carrier; and at least two surface stabilizers are disclosed. The present invention also comprises methods of treating various conditions with such a formulation and processes for making such a formulation.... Agent: Pfizer Inc Steve T. Zelson

20080166412 - Methods and materials for stimulating proliferation of stem cell: Disclosed herein are methods and materials for influencing proliferation of stem cells. Specifically exemplified herein are compositions comprising cerium oxide nanoparticles which can be used to stimulate proliferation of stem cells under common culture conditions, or which can be utilized to improve therapeutic outcomes.... Agent: Timothy H. Van Dyke

20080166413 - Topical pharmaceutical formulations and methods of treatment: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point... Agent: Davidson, Davidson & Kappel, LLC

20080166414 - Drugs and gene carrier particles that rapidly move through mucous barriers: The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.... Agent: Ropes & Gray LLP

20080166415 - Formulations containing microencapsulated essential oils: The present invention provides for a novel “green” agricultural formulation comprising at least one encapsulated volatile essential oil and a non-volatile vehicle in which said at least one encapsulated volatile essential oil is carried.... Agent: Nath & Associates

20080166416 - Multiparticle pharmaceutical dosage form for a low-soluble active substances and method for producing said pharmaceutical dosage form: The invention relates to an oral multiparticle pharmaceutical dosage form in the form of a receptacle reducing the pH values of stomach, containing a plurality of pellets, particles, granules or agglomerates whose mean diameter ranges from 50 to 2500 μn substentially consisting of a) an internal matrix layer containing an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080166417 - Method of relieving or avoiding side effect of steroid: The invention provides a method of relieving or avoiding a steroid-induced increase in intraocular pressure caused by the administration of asteroid. The steroid-induced increase in intraocular pressure can be relieved or avoided by incorporating a steroid in fine particles.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080166418 - Krill oil compositions: The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined... Agent: Jennings, Strouss & Salmon, P.L.C

20080166419 - Krill oil compositions: The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined... Agent: Jennings, Strouss & Salmon, P.L.C

20080166420 - Krill oil compositions: The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined... Agent: Jennings, Strouss & Salmon, P.L.C

20080166421 - Method of surgical treatment using autologous conditioned plasma: A method of providing autologous conditioned plasma (ACP) for treatment of connective tissue injuries. The method comprises the steps of: (i) providing an apparatus comprising a centrifuge and a double syringe, the double syringe including an inner syringe body and an outer syringe body; (ii) drawing autologous blood into the... Agent: Dickstein Shapiro LLP

20080166422 - Population of dairy cows producing milk with desirable characteristics and methods of making and using same: The invention relates to cows capable of producing milk low in total saturated fatty acids and high in mono- and poly-unsaturated fatty acids.... Agent: Wilmerhale/dc

20080166423 - Combination medication for treating the effects of stomach acid reduction medication on bone integrity: A composition for addressing a calcium deficiency caused by chronic administration of proton pump inhibitors and other acid lowering agents comprised of at least one proton pump inhibitor and vitamin D. The composition can further include one or more of the following: at least one buffering agent in an amount... Agent: Absolute Technology Law Group LLC

20080166424 - Compositions and methods for treatment of diseases of the foot of an animal: The present invention is directed to a method for treating the foot of an animal, including treatment of infectious diseases of the foot of an animal. Among the various aspects of the invention is provided a method of contacting a foot of an animal with an antimicrobial composition comprising water,... Agent: Sonnenschein Nath & Rosenthal LLP

20080166425 - Method for inhibiting cancer using arsenic trioxide: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080166426 - Anitbacterial compositions and methods of treatment: A composition and method of treatment for the Staphylococci, Streptococci, and Enterococcus faecalis Family of infections and their associated symptoms using Sangre de Grado (“SDG”). SDG is extracted from the lechleri Croton tree. SDG is formulated and administered to treat the Staphylococci, Streptococci, and Enterococcus faecalis Family of infections and... Agent: Williams Mullen

20080166429 - Anti-cancer phosphine containing [auiiim(cnc)ml]n+ complexes and derivatives thereof and methods for treating cancer using such compositions: Gold(III)phosphine complexes [Aum(CNC)mL]n+ (where HCNCH=2,6-diphenylpyridine) and their use as anti-tumor agents are disclosed. Notable results for the appearance of new potential anti-tumor application of these gold(III) complexes are reported. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080166427 - Method for reducing gastrointestinal toxicity due to the administration of tegafur: This invention provides a method for potentiating the antitumor effect of tegafur and reducing the gastrointestinal toxicity. The method comprises administering a composition containing tegafur, a DPD inhibitor and oxonic acid or a pharmaceutically acceptable salt thereof, to a patient under fasting conditions.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080166428 - Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound: A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated... Agent: Foley & Lardner LLP

20080166430 - Control of enterohemorrhagic e. coli in farm animal drinking water: The present invention relates to a new composition and methods for preventing the transmission of enterohemorrhagic E. coli and other foodborne pathogens to farm animals. In accordance with one embodiment, a composition comprising lactic acid and acidic calcium sulfate, and a compound selected from the group consisting of caprylic acid,... Agent: Barnes & Thornburg LLP

20080166431 - Smooth-feeling wax-based compositions for personal care preparations: A smooth, dry-feeling, less-greasy, substantially-odorless, ecotoxicologically-safe, wax-based composition with a melting point above 25° C., comprising one or more wax components selected from dialkyl carbonates, dialkylene carbonates, and mixtures of two or more thereof; less than 10%, by weight, of water; and (c) optionally, one or more components selected from... Agent: Cognis Corporation Patent Department

20080166432 - Biotherapeutics for mitigation of health disorders from terminalia arjuna: More particularly, the invention relates to certain extracts from Terminalia arjuna, their uses as antimicrobial and antioxidants agents for the treatment of certain diseases heart disease, diabetes, degenerative neurological diseases, cancer, age related disease like amyloidosis, acute pancreatitis, arthritis, atherosclerosis, cancer, cardiovascular disease, inflammatory bowel disease, myocardial infarction, senile dementia,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080166433 - Methods and composition for dietary supplements: Compositions and methods are provided to reduce glucose concentration in an organism. Particularly contemplated compositions include a compound that binds to a thaumatin-like protein and that is isolated from a plant. Contemplated compositions further reduce blood lipid concentrations at the concentration effective to reduce the glucose concentration.... Agent: Fish & Associates, PC Robert D. Fish

20080166434 - Diet supplement for burning additional calories, providing sustained energy, supporting weight loss, and/or improving mental focus: A diet supplement comprising at least Green Tea Extract and Oolong Tea Extract may be in a time-release mechanism for sustained all-day energy, burning of calories, supporting weight loss, and improving mental focus. A method for providing sustained all-day energy, burning of calories, weight loss support, and improved mental focus... Agent: Iovate Health Science Research Inc.

20080166435 - Composition and methods of use of an immunomodulator: A composition including one or more of elecampane rhizome (Inula sp.), fennel fruit (Foeniculum sp.), juniper berry (Juniperus sp.), licorice root (Glycyrrhiza sp.), oregano herb (Oreganum sp.), marigold flowers (Calendula sp.), rose hips (Rosa sp.), and thyme (Thymus sp.), or an extract thereof. The composition is useful for treating infectious... Agent: Connolly Bove Lodge & Hutz LLP

20080166436 - Composition for normalizing otitis externa in mammals: Otitis externa is a condition of the outer ear canal in mammalian animals, especially dogs and cats, marked by inflammation and infection of tissue, buildup of ear wax, and draining of ear exudate. Symptoms of infection are, among others, excessive cerumen, alopecia in the ear flap, crusts, and ear pruritis.... Agent: Harris Beach PLLC

20080166437 - Methods of reducing pests and treating gastrointestinal nematode infections: Methods for reducing pests (e.g., nematodes, oomycetes, fungi, viruses) in an object or area by applying to the object or area a pest reducing effective amount of a composition containing hydrogen peroxide, orange terpene oil, orange valencia oil, at least one non-ionic emulsifier, distilled water or deionized water, and optionally... Agent: Usda, Ars, Ott

20080166438 - Chromones as therapeutic agents: The present invention describes the identification and isolation of chromones and novel chromone compositions from plant sources that exhibit up-regulation of adiponectin production by adipocytes and the normalization of virtually hundreds of genes related to glucose and fatty acid metabolic and signaling pathways. The chromone compositions are effective in enhancing... Agent: Swanson & Bratschun, L.L.C.

20080166439 - Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof: A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %,... Agent: Ladas & Parry LLP

20080159955 - Ca ix-specific inhibitors: P

20080159954 - Metal chelates having a perfluorinated peg radical, processes for their preparation, and their use: The invention relates to the subjects characterized in the patent claims, namely metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use, processes for their preparation and their use in NMR and X-ray diagnosis, radiodiagnosis and radiotherapy, and in MRT lymphography.... Agent: Millen, White, Zelano & Branigan, P.c.

20080159956 - Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation: An antigen indicative of the presence of atherosclerotic plaque is provided. The antigen is used in a method for slowing or arresting progression and/or effecting regression of atherosclerotic plaque in a mammal, comprising administering to the mammal a binding agent having binding sites specific for said antigen of said mammal.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080159957 - Anti-cancer and anti-infectious disease compositions and methods for using same: The present invention provides methods and compositions for treating and/or preventing cancer in a subject via administration of a non-pathogenic virus. The present invention also provides methods and compositions for treating and/or preventing infectious diseases in a subject via administration of a non-pathogenic.... Agent: Novartis Vaccines And Diagnostics Inc.

20080159958 - Determination of histamine-3 bioactivity: The invention relates to an in vivo method for determining the bioactivity of chemical compounds as histamine-3 receptor (H3R) ligands, and provides animal models to determine such bioactivity. The invention further relates to methods for screening therapeutic compounds demonstrating a desired property, using such methods and models described.... Agent: Paul D. Yasger Abbott Laboratories

20080159959 - Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the... Agent: Needle And Rosenberg

20080159960 - Particles for determining the local temperature: The invention relates to particles for determining the local temperature in organic and non-organic bodies. The temperature is determined using nuclear magnetic resonance spectroscopy (NMR) when the particles are utilized. The aim of the invention is to provide temperature sensors which allow the temperature to be measured in vivo in... Agent: Collard & Roe, P.c.

20080159965 - Adhesive block ethylenic copolymers, cosmetic compostions containing them and cosmetic use of these copolymers: e

20080159963 - Devices and methods for delivering active agents to target sites: The subject invention provides novel, inexpensive, and highly effective methods and devices for convenient and effective wound irrigation. In one embodiment the subject invention provides a discharge means for a reservoir housing containing irrigation solution wherein the discharge means has one or more specifically designed nozzles through which a sufficient... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080159961 - Pharmaceutical composition: A pharmaceutical composition for administration as an aerosol, which comprises a cannabinoid, a propellant and an effective amount of a cough suppressant.... Agent: Martin A. Hay & Co.

20080159964 - Use of adenosine deaminase for treating pulmonary disease: Provided are methods for treating an adenosine deaminase-mediated pulmonary disease such as asthma, pulmonary fibrosis, cystic fibrosis and chronic obstructive pulmonary disease in a mammal in need thereof, by administering and effective amount of a polymer-conjugated adenosine deaminase.... Agent: Lucas & Mercanti, LLP

20080159962 - Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries: The invention relates to the use of Angiotensin Converting enzyme 2 (ACE2) for the preparation of a medicament for the treatment of severe acute lung injury, especially induced by acid aspiration or sepsis, of lung oedemas and lung injuries and failures connected with infection with severe acute respiratory Syndrome (SARS)... Agent: Fulbright & Jaworski L.l.p.

20080159966 - Multiphase toothpaste composition: Multiphase toothpaste composition comprising a first phase disposed co-axially within a second phase, each of the phases having a viscosity of from 180 000 to 250 000 mPa·s.... Agent: Unilever Patent Group

20080159967 - Dentifrices comprising biogenic silica materials and at least one calcium phosphate: Unique dentifrices comprising unique abrasive biogenic silica materials are provided. Such compositions exhibit excellent abrasive characteristics, either alone, or in combination with other types of abrasives. In such combinations (with precipitated silica materials, as one example), simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels are possible in... Agent: J.m. Huber Corporation Legal Department

20080159968 - Dentifrices comprising biogenic silica materials and calcium carbonate: Unique dentifrices comprising unique abrasive biogenic silica materials are provided. Such compositions exhibit excellent abrasive characteristics, either alone, or in combination with other types of abrasives. In such combinations (with precipitated silica materials, as one example), simultaneously high pellicle film cleaning properties and moderate dentin abrasion levels are possible in... Agent: J.m. Huber Corporation Legal Department

20080159970 - Kit comprising silicone compounds and a cosmetic and/or dermatological active agent: i

20080159969 - Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent: The invention relates to a pharmaceutical or cosmetic composition comprising, in a physiologically acceptable medium, mequinol and at least one depigmenting agent, and to the use thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080159971 - Use of dhea or precursors or metabolic derivatives thereof as a depigmenting agent: The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080159972 - Process for the preparation of aqueous suspensions of anionic colloidal silica having a neutral ph and applications thereof: The instant invention relates to a process for the preparation of an aqueous suspension of anionic colloidal silica having a neutral pH which is stable over time and comprises individualized particles of colloidal silica which are not bound to one another by siloxane bonds. The instant suspensions show high storage... Agent: Clariant Corporation Industrial Property Department

20080159973 - Durable nail coating composition and method of use thereof: A durable nail coating composition comprising a one-to-one mixture of acrylic polymeric coatings, wherein the durable nail coating composition is applied to the portion of the nail extending forward of the fingertip. The durable nail coating composition is applied via a process that includes selectively installing a new nail set... Agent: Williamson Intellectual Property Law, Llc

20080159974 - Lip plumping cosmetic composition: A cosmetic composition is provided that is particularly intended for application to areas constituting or surrounding the lips. The cosmetic composition contains a viscosity increasing agent as its base, marine collagen, red dye, and a cooling agent. The composition is specifically designed to temporarily enhance the fullness of the lips.... Agent: Ward & Olivo

20080159975 - Hair treatment composition, hair treatment agent and method for treating hair by using the same: The present invention provides a hair treatment composition comprising a multi-arm polyethylene glycol derivative (A) that contains two or more functional groups that may be covalently bound to amines, a hair treatment agent comprising the composition, and a method for using the same. Optionally, the composition may further comprise a... Agent: Edwards Angell Palmer & Dodge LLP

20080159976 - Methods for lowering elevated uric acid levels using intravenous injections of peg-uricase: Disclosed is a method for lowering elevated uric acid levels in a patient having a plasma level of uric acid (pUAc) of more than about 6 mg/dL, the method consisting of administering to said patient an intravenous injections every 2 to 4 weeks of about 8 mg PEG-uricase.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20080159978 - Methods for accelerating wound healing by administration of adipokines: Methods for inducing or accelerating a healing process of a damaged skin or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or... Agent: Fulbright & Jaworski, LLP

20080159977 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Fish & Richardson, Pc

20080159980 - Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy: A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST- activated anticancer compound (including chemotherapy;... Agent: Foley & Lardner LLP

20080159982 - Hepatitis c virus inhibitors: m

20080159981 - Methods of therapy for cancers characterized by overexpression of the her2 receptor protein: Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2... Agent: Novartis Vaccines And Diagnostics Inc.

20080159979 - Treatment of wounds using il-17b: IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in... Agent: Zymogenetics, Inc. Intellectual Property Department

20080159983 - Interleukin-15 antagonists for the treatment of anemia: The present invention relates to methods and compositions for the prevention and treatment of anemia. Anemia is characterized by a deficiency in red blood cells (RBCs) or hemoglobin, thereby reducing the supply of oxygen to tissues and organs. The invention is based on the discovery that interleukin-15 (IL-15) acts downstream... Agent: Kenyon & Kenyon LLP

20080159984 - Compositions capable of facilitating penetration across a biological barrier: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080159985 - Electroprocessing in drug delivery and cell encapsulation: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080159986 - Modulators of the functions of receptors of the tnf/ngf receptor family and other proteins: Proteins which are capable of modulating/mediating the function of RIP, their preparation and uses are provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080159999 - Compositions and methods for identifying, isolating and enriching germline-like stem cells from amniotic fluid: The present invention is directed to pluripotent embryonic stem cells derived from amniotic fluid and the methods for isolating, expanding and differentiating these cells, and their therapeutic uses such as manipulating the cells by gene transfection and other means for therapeutic applications.... Agent: The Nath Law Group

20080159996 - Methods and compositions for gene inactivation: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs... Agent: Robins & Pasternak

20080159998 - Stem cell mediated treg activation/expansion for therapeutic immune modulation: Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or... Agent: Marc Baumgartner Baumgartner Patent Law

20080159997 - Transplants for myocardial scars: A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.... Agent: Genzyme Corporation Legal Department

20080159988 - Materials and methods for treating or preventing oxalate-related disease: A method for treating, preventing, controlling, or impeding a disease in a human and non human wherein said method comprises administering to said human a composition comprising a material selected from the group consisting of oxalate-degrading microbes and oxalate-degrading enzymes. A composition for treating, preventing, controlling, or impeding a disease... Agent: Bio Intellectual Property Services (bio Ips) Llc

20080159987 - Use of rifaximin for the treatment of restless legs syndrome: Restless legs syndrome (RLS) is characterized by an urge for leg movement, often with abnormal leg sensations. Symptoms are triggered by rest, often at night, and improve temporarily with movement, especially walking. This syndrome has a prevalence ranging from 7% to 15% and significantly contributes to sleep disorders. A method... Agent: Husch Blackwell Sanders LLP

20080160000 - Coccidiosis and clostridial disease prophylactic and/or therapeutic feed for coccidiosis and clostridial disease: There is provided an animal feed, an anticoccidial agent, and an anticlostridial agent having less harm and an excellent prophylactic and/or therapeutic effect for coccidiosis and clostridial disease. Also provided is a prophylactic and/or therapeutic feed for coccidiosis containing pinene, thymol, eugenol, and limonene; an anticoccidial agent containing pinene, thymol,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080159990 - Adsorbent for lymphocyte proliferation inhibitor and treating method: The invention relates to a porous material for body fluid treatment for promoting lymphocyte proliferation in lymphocyte culture which contains a high-molecular compound having an angle of contact with water within the range of 40° to 98 °; and a porous material for body fluid treatment which comprises activated carbon.... Agent: Connolly Bove Lodge & Hutz LLP

20080159992 - Hepatocyte growth factor receptor splice variants and methods of using same: Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are... Agent: Fennemore Craig

20080159993 - Immunotherapeutic methods using epitopes of wt-1 and gata-1: A peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or... Agent: Olson & Cepuritis, Ltd.

20080159989 - Method of promoting the differentiation of staminal cells: A method is described by which stem cells are induced to differentiate into cardiomycocytes; the method comprises exposure for a length of time and at efficacious quantities of a protein of the EGF-CFC family or its derivitaies having at least the EGF and CFC domains; or to differentiate into neuronal... Agent: Law Offices Of Albert Wai-kit Chan, Pllc

20080159994 - Methods for embryonic stem cell culture: The invention relates to a method of cell culture comprising providing a pluripotent ES cell encapsulated within a support matrix to form a support matrix structure, maintaining the encapsulated cell in 3-D culture in maintenance medium, and optionally differentiating the encapsulated cell in 3-D culture in differentiation medium. The invention... Agent: Frommer Lawrence & Haug

20080159991 - Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof: The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.... Agent: Darby & Darby P.c.

20080159995 - Treatment of fibrosis: The present invention relates to methods and compositions for treating fibrosis. In one aspect the invention provides the use of an agent capable of increasing the number of stem cells and/or progenitor cells available to and/or engraftment at a site of fibrosis in the manufacture of a medicament for use... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080160001 - Antihypercholesterolemic formulation with less side-effects: The present disclosure provides a combined medicament for reducing blood fat with safety and high efficiency, the active ingredients of which include an agent for lowering blood fat such as statins; an agent for protecting and repairing liver such as silymarin; an agent for protecting kidney, heart, blood vessel or... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080160003 - Fertility enhancement using lipid carriers and bioactive molecules: The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/ApoJ, a well-known lipid carrier.... Agent: Mccarter & English, LLP Basil S. Krikelis

20080160004 - Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate: The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate... Agent: Frommer Lawrence & Haug

20080160002 - Pharmaceutical compositions for treating arthritis and inflammatory disease: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active... Agent: Bozicevic, Field & Francis LLP

20080160005 - Interleukin-6 suppressive agent: An interleukin-6 suppressive agent comprising lactoperoxidase as an active ingredient is used as a pharmaceutical preparation or the like for prevention and/or therapy of a disease caused by production of interleukin-6, such as thrombocytosis, myeloma, Castleman syndrome, rheumatoid arthritis, or influenza-virus infectious disease.... Agent: Knobbe Martens Olson & Bear LLP

20080160006 - Nutrient medium for maintaining neural cells in injured nervous system: A method to improve neural cell viability in brain or spinal cord tissue after brain or spinal cord injury or surgery is provided. This method comprises applying a sterile liquid medium to the brain or spinal cord tissue, wherein the sterile aqueous liquid medium comprises 0 to about 3000 μM... Agent: Fitch Even Tabin And Flannery

20080160007 - Diagnosis and treatment of cancer related to human dormancy: New devices and methods for diagnosis and compositions and methods for treatment of cancers use combinations of antimicrobial agents and agents that can reverse dormancy and hibernation pathways. We unexpectedly found that surprisingly low doses of anti-hibernation compounds can substantially inhibit cancer cell growth in vitro and can successfully treat... Agent: Borson Law Group, Pc

20080160008 - Methods and compositions for reducing amyloid beta levels: The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant... Agent: Bozicevic, Field & Francis LLP

20080160011 - Alpha-synuclein kinase: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.... Agent: Townsend And Townsend And Crew, LLP

20080160012 - Antibodies against cancer antigen tmeff2 and uses thereof: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080160009 - Inhibiting cav3 isoforms and the 25b splice varients for the diagnosis and treatment of cancer: The invention provides a pharmaceutical composition comprising an antibody that specifically binds to a Cav3 isoform or its δ25 splice variants thereof. The present invention also relates to compositions and methods for inhibiting cancer cell proliferation, preventing, treating and/or controlling cancer and/or related disorders in a patient by administering to... Agent: Scully Scott Murphy & Presser, Pc

20080160013 - Method for inhibiting cellular activation by insulin-like growth factor-1: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation... Agent: Myers Bigel Sibley & Sajovec

20080160010 - Peptide that elicits neutralizing antibodies targeting the hiv co-receptor: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant... Agent: National Institutes Of Health C/o Venable LLP

20080160014 - Protein formulations with reduced viscosity and uses thereof: Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.... Agent: Wilmerhale/wyeth

20080160015 - Anti-idiotypic antibodies neutralizing the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly... Agent: 24ip Law Group Usa, Pllc

20080160016 - Compositions and methods of tolerizing a primate to an antigen: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20080160017 - Cross-linked antibodies: The present invention provides a compound consisting essentially of the following elements: one or more reactive groups; and two or more cross-linked antibodies or fragments thereof; characterised in that the or each reactive group is suitable for attaching an effector molecule but does not react with any of the antibodies... Agent: Woodcock Washburn LLP

20080160018 - Humanized immunoglobulins: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino... Agent: Townsend And Townsend And Crew, LLP

20080160021 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent: Heller Ehrman LLP

20080160022 - Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.... Agent: Mandel & Adriano

20080160020 - Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells: The present invention relates to a method for inhibiting a disease response in a subject comprising contacting dead or dying cells exposing an antigen selected from the group consisting of a phosphorylcholine (PC) determinant, a phosphatidyl serine (PS) determinant, a MDA determinant, and cardiolipin in the subject, with an antibody... Agent: Mandel & Adriano

20080160023 - Pharmaceutical composition for treating and diagnosing a disorder associated with peroxisomal biogenesis and function: The invention relates to a pharmaceutical composition for treating or diagnosing a disorder associated with production of peroxisome in a cell, comprising a polypeptide which has cysteine protease activity and directly processes peroxisomal enzymes targeted by PTS1 or PTS2 signals. Preferably, the polypeptide is encoded by Tysnd1.... Agent: Edwards Angell Palmer & Dodge LLP

20080160019 - Sequential combination therapy: Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a VEGF antagonist agent.... Agent: Lowrie, Lando & Anastasi, LLP

20080160024 - Inhibition of cancer metastasis: The present invention provides a method for inhibiting tumor cell metastasis in a subject. In particular, the method comprises administering a glycoprotein lbα inhibitor to the subject. The method may also be used for reducing tumor cell malignancy or inhibiting formation of a tumor cell embolism.... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080160026 - Apo-2 ligand-anti-her-2 antibody synergism: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.... Agent: Genentech, Inc.

20080160025 - Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions: The use is provided of a calcitonin in the preparation of a medicament for the treatment of an inflammatory disease or condition. The calcitonin may be selected from the group consisting of human, salmon, eel, porcine, bovine, or chicken calcitonin or a derivative, a fragment or a variant thereof. The... Agent: Pepper Hamilton LLP

20080160027 - Chlamydia pneumoniae vaccine and methods for administering such a vaccine: The present application relates to antigens and nucleic acids encoding such antigens obtainable by screening the Chlamydia pneumoniae genome. In more specific aspects, the present application relates to methods of isolating such antigens and nucleic acids and the methods of using such isolated antigens for producing immune responses. The ability... Agent: Andrus, Sceales, Starke & Sawall, LLP Suite 1100

20080160028 - Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha: The invention relates to compounds of general formula (I); 1a, 1 b, 1 c and 1 d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical... Agent: Frommer Lawrence & Haug

20080160030 - Anti-interferon alpha monoclonal antibodies and methods for use: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity... Agent: Hutchison Law Group Pllc

20080160029 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20080160031 - Method and composition for treatment of neoplasms: The invention relates to methods of treating a neoplasm in an animal, in particular treating a neoplasm in a human, through the use of isolated nucleic acid sequence, including synthetic viral RNA and complementary DNA, derived from one or more Picornaviruses. The invention also relates to compositions of isolated nucleic... Agent: Seed Intellectual Property Law Group Pllc

20080160032 - Compositions and methods for the systemic treatment of arthritis: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.... Agent: Chalker Flores, LLP

20080160035 - high affinity human antibodies to human il-4 receptor: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.... Agent: Regeneron Pharmaceuticals, Inc

20080160034 - Novel gene disruptions, compositions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298,... Agent: Genentech, Inc.

20080160033 - Novel screening method: By using a G protein-coupled receptor protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, or a salt thereof, and a fatty acid, a compound or its salt that changes the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080160036 - Compositions and methods for treating inflammation and auto-immune diseases: Compositions containing soluble B7-H4 (sH4) antagonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders are provided. Soluble H4 has been discovered to interfere with B7-H4 activity including B7-H4's... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080160037 - Novel beta-defensins: The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the β-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080160038 - Non-anaphylactic forms of grass pollen ph1 p 6 allergen and their use: Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phi p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding... Agent: Dinsmore & Shohl, LLP

20080160040 - Plant-produced compositions for treating papillomavirus infection and related methods: Compositions for treating papillomavirus (PV) infection in a subject include a PV L2 polypeptide produced from a eukaryotic expression system.... Agent: Stites & Harbison, Pllc

20080160039 - Pneumovirus ns proteins antagonize the interferon ifn response: The present invention relates to the use of a pneumovirus NS1 protein and/or NS2 protein or a nucleic acid encoding pneumovirus NS1 protein and/or NS2 protein for the preparation of a pharmaceutical formulation for reducing the immune response mediated by interferon (IFN). The invention further relates to recombinant pneumoviruses, in... Agent: Wyeth Patent Law Group

20080160041 - Composition and method for modulating dendritic cell-t cell interaction: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in... Agent: Ropes & Gray LLP

20080160042 - Hepato phyto-nutraceutical synergistic composition: Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20080160043 - Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same: Disclosed herein is a method for high-yield production of Schizophyllum commune-derived beta-glucan having a homogeneous composition, comprising subjecting mycelia of Schizophyllum commune to liquid culture with an addition of a synthetic adsorbent, and a composition for external application comprising the beta-glucan produced therefrom, which is capable of relieving dry skin... Agent: Birch Stewart Kolasch & Birch

20080160044 - Soy peptone as a nitrogen source in preparing meningcoccal conjugates: A method for preparing a protein-saccharide conjugate, comprising the steps of: (a) preparing an aqueous growth medium comprising soy peptone as a nitrogen source; (b) inoculating the medium with a Neisseria meningitidis bacterium; (c) incubating the medium to allow growth of the bacterium; (d) preparing capsular saccharide from the bacterium;... Agent: Novartis Vaccines And Diagnostics Inc.

20080160045 - Vaccines comprising aluminum adjuvants and histidine: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a... Agent: Novartis Vaccines And Diagnostics Inc.

20080160046 - Gm-negative ehv-mutants: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080160047 - Oil in water emulsions containing saponins: A composition comprising an oil in water emulsion and a saponin, wherein said oil is a metabolisable oil, and having an advantageous ratio of metabolisable oil:saponin (w/w).... Agent: Glaxosmithkline Corporate Intellectual Property

20080160048 - Nucleic acid constructs: A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a hCMV immediate early promoter sequence; (b) exon 1 and at least a part of exon 2... Agent: Foley And Lardner LLP Suite 500

20080160050 - Dendritic cell tumor injection therapy and related vaccine: The present invention provides effective, safe, comprehensive combinatorial treatment methods that are safe and effective for reducing the size of tumor cells in tumor tissue of a patient. The methods include reducing the size of tumor cells in tumor tissue of a patient by collecting monocyte cells from a patient;... Agent: Eckert Seamans Cherin & Mellott

20080160049 - Tissue vaccines and uses thereof: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations... Agent: Bell, Boyd, & Lloyd LLP

20080160051 - Hemostatic substance with a coating: A hemostatic device includes a dissolvable coating and a hemostatic substance enclosed within the coating. The device can have, for example, a generally spherical shape. The hemostatic substance can be particles that take any shape, such as spherical, flat sheets, cubes, or other regular or irregular shapes of any size... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20080160053 - High electrolyte additions for precipitated silica material production: Precipitated silica comprising porous silica particles having a cumulative surface area for all pores having diameters greater than 500 Å of less than 6 m2/g, as measured by mercury intrusion, and a percentage cetylpyridinium chloride (% CPC) Compatibility of greater than about 85%. The precipitated silica product is especially well-adapted... Agent: J.m. Huber Corporation Legal Department

20080160054 - Novel elongase gene, and process for the preparation of polyunsaturated fatty acids: Furthermore, the invention relates to a process for the preparation of polyunsaturated fatty acids and to a process for introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids. Moreover, the invention relates to an oil and/or a... Agent: Novak Druce Deluca + Quigg LLP

20080160056 - Oral and personal care compositions and methods: A dentifrice composition comprising an orally acceptable vehicle having distributed therein a water hydratable film flakes having a matrix comprised of a water soluble hydroxy alkyl cellulose polymer and a starch, and having entrained therein a constituent selected from therapeutic cosmetic and decorative materials.... Agent: Colgate-palmolive Company

20080160052 - Precipitated silica materials exhibiting high compatibility with cetylpyridinium chloride: Precipitated silica comprising porous silica particles having a cumulative surface area for all pores having diameters greater than 500 Å of less than 6 m2/g, as measured by mercury intrusion, and a percentage cetylpyridinium chloride (% CPC) Compatibility of greater than about 85%. The precipitated silica product is especially well-adapted... Agent: J M Huber Corporation

20080160055 - Prophylactic cleaning product and method of packaging: A prophylactic (prophy) paste composition comprising about 40 percent by weight to about 55 percent by weight expanded perlite comprising perlite granules in the range of about 20 μm to about 70 μm and floaters. The prophy paste composition further comprises no more than 5 percent by weight of a... Agent: Wood, Herron & Evans, LLP

20080160057 - Antimicrobial construction: A construction includes a substrate incorporating an activatable antimicrobial composition. The substrate includes a laminate having at least two layers bonded together by a thermoplastic bonding medium. The antimicrobial composition includes a peroxygen donor and an acid and/or an acid-producing substance. The peroxygen donor is incorporated separately and in a... Agent: Egbert Law Offices

20080160058 - bait and uses thereof: A bait for omnivorous feral animals comprising a core in physical contact with a solid or semi-solid carrier material wherein the core contains an active agent and the core is located within the solid or semi-solid carrier material.... Agent: Wolf Greenfield & Sacks, P.c.

20080160059 - Antibiotic/antimycotic preparation and use in plants: The present invention refers to a fungicide/bactericide formulation comprising oxytetracycline hydrochloride and copper oxychloride for use in plants.... Agent: Bell, Boyd, & Lloyd LLP

20080160060 - Methods of altering bone growth by administration of sost or wise antagonist or agonist: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may... Agent: Fitzpatrick Cella Harper & Scinto

20080160063 - Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the... Agent: William J Bundren The Law Office Of William J Bundren

20080160064 - Devices and methods for inhibiting fibrosis: The present invention relates to compositions and methods for rendering medical devices less prone to fibrous encapsulation comprising the use of non-gaseous CO dissolved in a reservoir material. Upon exposure to a biological environment, non-gaseous CO is slowly desorbed and/or dissolved from the reservoir material which provides anti-fibrotic activity. These... Agent: Fulbright & Jaworski L.l.p.

20080160061 - Implantable devices for accelerated healing: Implantable devices (e.g., stent) having a protein patterning or bioactive patterning for accelerated healing and method of forming and using the same are provided.... Agent: Squire, Sanders & Dempsey LLP

20080160062 - Medical devices based on modified polyols: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain at least one region of polymeric material. The at least one region of polymeric material contains at least one polymer selected from the following (a) at least one polymer that contains a polyol... Agent: Mayer & Williams Pc

20080160065 - Drug delivery polymer with hydrochloride salt of clindamycin: One embodiment provides an insert, which includes a non-degradable hydrogel matrix and clindamycin hydrochloride in contact with the matrix, wherein the insert is suitable for mammalian intravaginal, buccal, or intrarectal use. Methods of using and making the insert are also provided.... Agent: Law Office Of John K. Pike, Pllc

20080160066 - Phospholipid derivatives of dha and methods for treating respiratory failure using the same: Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.... Agent: Matthias Scholl

20080160067 - Novel soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations: This document relates to formulations for combating bacterial infections in animals which provide for improved long-acting oral and injectable formulations for systemic delivery of antibiotics, which are designed to achieve high bioavailability.... Agent: Judy Jarecki-black, Ph.d,j.d

20080160069 - Constricting gel assay and therapeutic patch: Method and compositions relate diagnostic tools to determine invasive potential of tumor cells. Therapeutic patches include a component from the extracellular matrix seeded with tumor cells from an individual and a fibrin backing. Extracellular matrix-based constriction assays are useful to screen for anti-tumor compounds.... Agent: Barnes & Thornburg LLP

20080160068 - Method for a medicinal combination treatment, and medicament combinations suitable therefor: A method for the administration of at least one pharmaceutical agent to a patient who depends on the administration of the agent or agents, comprising the application of at least one transdermal therapeutic system containing a first pharmaceutical agent for the transdermal administration of the agent during a predeterminable period... Agent: D. Peter Hochberg Co. L.p.a.

20080160070 - Transdermal vitamin b12 delivery patch: A transdermal vitamin B12 delivery patch is applied to the skin of a user for the delivery of vitamin B12 to the bloodstream of the user. The patch includes a fabric backing and a skin-adhesive polymer matrix that is attached to one side of the fabric backing. The matrix contains... Agent: David P Dureska Buckingham Doolittle & Burroughs, LLP

20080160071 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20080160072 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20080160073 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical compositions comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20080160074 - Pharmaceutically acceptable phosphate-glycerol carrying bodies: This invention relates to three-dimensional synthetic and semi-synthetic compositions having biological activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly it relates to preparations and uses of synthetic and semi-synthetic bodies, such as liposomes, which after introduction into the body... Agent: Foley & Lardner LLP

20080160075 - Pharmaceutical composition made from chinese traditional medicine and method of producing thereof: A method of preparing a Chinese medicine for treatment of diabetes, the medicine including the Radix Rehmanniae Preparata, prepared Asiatic Comelian Cherry fruit, tree peony bark, Common Yam Rhizome, Indian bread, Oriental Waterplain rhizome, and refined edible vegetable oil. The tree peony bark is distilled and its residue, the Radix... Agent: Banner & Witcoff, Ltd.

20080160076 - Two-part capsule to accept pharmaceutical preparations for powder inhalers: The present invention relates to capsules for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to their use in powder inhalers. The capsules consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080160078 - Nanoparticles for drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent of HMG-CoA reductase inhibitors or erythropoietin. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20080160077 - Soft gel formulations: This invention relates to an improved formulation methodology for bioactive lipophilic molecules, such as Coenzyme Q10 (CoQ10) and its reduced analogs (ubiquinols). Further provided are methods of producing soft gel capsules of this formulation.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080160080 - Amorphous solid dispersions: Disclosed are amorphous solid dispersion formulations comprising 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080160079 - Capsule medication administration system and medication administration method: A capsule medication administration system includes: a first capsule for internal body marking; a second capsule for medication; a marking device which makes a marking within a living body; a drug retention section which retains a drug; a release device which releases the drug; a detection device which detects the... Agent: Scully Scott Murphy & Presser, Pc

20080160081 - Alfuzosin formulations, methods of making, and methods of use: Alfuzosin compositions comprising alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 are disclosed. Alfuzosin compositions comprising alfuzosin and a release-retarding... Agent: Cantor Colburn, LLP

20080160082 - Controlled release compositions comprising nimesulide: A controlled release pharmaceutical composition for peroral administration including a single unit fast release fraction and a single unit extended release fraction which includes nimesulide as an active drug upto 99% w/w of the composition, one or more release controlling materials from 0.1% to 99% w/w of the composition and... Agent: Ladas & Parry LLP

20080160083 - Composition and method for treatment of premenstrual symptoms: The present invention is a composition delivering effective amounts of Chasteberry Extract, Pyridoxine, and Magnesium in a single dosage unit and a method of treating PMS and related disorders with the composition.... Agent: Robert M. Schwartz, P.a.

20080160084 - Natural water-insoluble encapsulation compositions and processes for preparing same: The present invention relates to dry particulate encapsulation compositions comprising a water-insoluble matrix comprising at least 70% by weight of proteins, based on the total weight of the matrix and a moisture content of about 5 to 10% by weight, based on the total weight of the matrix and an... Agent: Venable LLP

20080160085 - Cell delivery matrices: Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080160086 - Delivery systems for calcium: Oral gel delivery systems for calcium are provided comprising an ingestible matrix within which a calcium source is substantially uniformly and completely dispersed. The delivery systems may optionally include one or more other functional ingredients, for example, functional ingredients that aid in the uptake and/or metabolism of calcium by the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080160087 - Gel preparation for oral administration: Provided for use in medical care settings is a gel preparation for oral administration to patients with hyperlipemia or hypercholesterolemia, wherein the ingestibility of an HMG-CoA reductase inhibitor, also known as a statin-series compound, has been improved in dosage forms of tablets, granules and liquids. A pharmaceutical composition in a... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080160091 - Composite materials comprised of calcium compounds and protein components: An oral and dental hygiene product is comprised of a composite material comprising calcium salts which are slightly soluble in water, in the form of nanoparticulate primary particles having a length of from 5 to 150 nm and a cross section of from 2 to 50 nm and protein components... Agent: Paul & Paul

20080160093 - Composition comprising particulate zinc materials having a defined crystallite size: The present invention discloses a composition comprising a particulate zinc material wherein the particulate zinc material has a crystallite size less than 600 Å. The present invention further comprises a shampoo composition comprising an effective amount of a surfactant, an effective amount of a particulate zinc material, an effective amount... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080160088 - Composition containing hydroxyapatite and a calcium salt: Composition containing, preferably in a physiologically acceptable medium, at least hydroxyapatite that is at least partially in free form and at least one calcium salt. Method of use. The invention method and composition is preferably used for preventing and/or reducing the embrittlement of the skin and/or semi-mucous membranes and/or for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080160090 - Laser-activated nanothermolysis of cells: Provided herein are methods and system to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or... Agent: Benjamin Aaron Adler Adler & Associates

20080160092 - Use of simple amino acids to form porous particles: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter... Agent: Elmore Patent Law Group, Pc

20080160089 - Vaccine delivery compositions and methods of use: The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants. The vaccines can be formulated as a liquid dispersion of polymer particles... Agent: Dla Piper Us LLP

20080160094 - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080160095 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20080160096 - Polymeric nanoparticles by ion-ion interactions: The present invention relates to biocompatible and biodegradable stimuli-sensitive polymeric nanoparticles, which were formed by ion-ion interaction in aqueous media. Synthetic and biological macromolecules with ionizable functional groups are capable of forming nanoparticles whose size and surface properties are sensitive to environmental influences such as pH, temperature and salt concentration.... Agent: Thomas A. O'rourke Bodner & O'rourke

20080160097 - Method for imparting a cosmetic or therapeutic benefit to a topical surface and process for making: There is disclosed a method of imparting a cosmetic or therapeutic benefit to a topical surface. The method has the steps of a) providing a polymer powder having a plurality of substantially nonporous polymer particles with a number average particles size of about 0.1 to about 0.5 microns in diameter;... Agent: Charles N. J. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.l.p.

20080160098 - Use of simple amino acids to form porous particles: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter... Agent: Elmore Patent Law Group, Pc

20080160099 - Methods for treating or preventing a vascular disease: The present invention relates to green tea and sea cucumber extracts, compositions thereof, and methods of treating or preventing a cardiovascular disease, a peripheral vascular disease, or an aneurysm in a subject, the methods comprising administering to the subject an effective amount of a green tea extract, a sea cucumber... Agent: Wilmerhale/columbia University

20080160100 - Method for stimulating hair growth and regeneration: The invention relates to method for stimulating hair growth and regeneration in a mammal in need thereof, which comprises a step of applying to the skin of said mammal an effective amount of water comprising from about 99.760 to about 99.999% of light isotopologue 1H2160 and up to 100% of... Agent: Notaro And Michalos

20080160101 - Composition for use against one or more pathogens: The present invention relates to a composition for use against one or more pathogens, comprising at least one antagonistic micro-organism and at least one salt and/or derivatives thereof as defined in claim 1. The present invention further relates to said composition for use as biopesticide.... Agent: Sughrue Mion, Pllc

20080160102 - Compositions for disfecing inanimate surfaces: This invention relates to compositions for disinfecting an inanimate surface comprising an effective disinfecting amount of a disinfectant and water, which water comprises from about 99.760 to about 99.999% of light isotopologue 1H2 160 and up to 100% of residual isotopologues 1H2170, 1H2180, 1H2H160, 1H2H170, 1H2H180, 2H2160, 2H2170, and 2H2180.... Agent: Notaro And Michalos

20080160103 - Pharmaceutical gallium compositions and methods: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation... Agent: Diehl Servilla Llc

20080160104 - Antimicrobial composition: An antimicrobial composition prepared by mixing a polymer-ammonium salt formulation comprising one or more polymers and one or more ammonium salts with alkali and a chlorine source in a molar ratio of chlorine (as Cl2) to ammonium ion of about 1:10 to about 10:1 and methods of using the composition... Agent: Nalco Company

20080160105 - Methods and compositions for treatment of preeclampsia: Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing or predicting a pregnancy related disease or disorder The methods involve detection of 2-methoxyestradiol, or a... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080160106 - Novel uses for proton pump inhibitors: Proton pump inhibitors such as omeprazole, on their own, are able to exert antineoplastic effects on solid tumours, and are able to substantially completely restore drug sensitivity to such tumours, where resistance is presented, when used as pre-treatment.... Agent: Greenlee Winner And Sullivan P C

20080160108 - Method of treating muscular dystrophies with an inhibitor of histone deacetylase: The present invention relates to the use of an inhibitor of histone deacetylase for preparing a drug for the treatment or prevention of a disease resulting from the deficiency of an adult gene in an individual by the re-expression of the homologous fetal gene. The invention concerns in particular the... Agent: Ip Group Of Dla Piper Us LLP

20080160107 - Use of nitric oxide gas to treat blood and blood products: The present invention relates to compositions and methods for treatment of blood and blood products using gaseous nitric oxide. The treatment involves the contacting blood or a blood product with gaseous nitric oxide.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080160110 - Anti-aging cosmetic composition: The present invention relates to an anti-aging cosmetic composition, and more particularly, the present invention relates to an anti-aging cosmetic composition containing Hibiscus esculentus extracts and at least one selected from the group consisting of oleanolic acid, ursolic acid, glycyrhetinic acid and retinol, showing high safety to skin and wrinkle-improvement... Agent: Nixon & Vanderhye, Pc

20080160109 - Compositions and methods of their use for improving the condition and appearance of skin: The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents, or synthetic equivalents thereof, which inhibit or decrease expression of... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20080160112 - Pharmaceutical use of water-soluble fraction of graptopetalum: The present invention relates to a pharmaceutical composition containing a water-soluble fraction of Graptopetalum and its use in treating a liver disease or condition, such as inflammation, steatosis, and fibrosis.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080160111 - Type i allergy inhibitor and methods of inhibiting the onset of type i allergy using fulvic acid: The present invention provides a type I allergy inhibitor which inhibits an antigen sensitization phase or/and an antibody sensitization phase, and the degranulation phase of cells with fulvic acid and a composition containing at least the fulvic acid. Moreover, the present invention provides a method for inhibiting the onset of... Agent: Jordan And Hamburg LLP

20080160113 - Compositions for the regression of dermal vessel tortuosity: Herbal compositions that, when used topically in a therapeutically effective amount, are safe and effective for the regression of dermal vessel tortuosity in patients exhibiting chronic inflammatory skin disorders, such as psoriasis. The compositions, which can be formulated as ointments, oils, soaps and shampoos, comprise a non-aqueous herbal extract of... Agent: Bregen Technical Consultants L.l.c.

20080160114 - Composition of skin external application containing rose extract and epigallocatechin gallate(egcg): The present invention relates to a composition of skin external application comprising rose extracts and epigallocatechin gallate (EGCG) as effective ingredients, more particularly to a composition of skin external application that contains rose extracts and EGCG, thereby promoting the synthesis of collagen fiber to promote superior skin elasticity and skin... Agent: Nixon & Vanderhye, Pc

20080160115 - Method, substance and device to prevent the flow of mother's milk: Extracts, in the form of cream, ointment and the like, from cabbage leaves to reduce or to prevent the flow of mother's milk when applied to the mother's breast. A pad with such extracts to fit on a breast. Vacuum sealed pads.... Agent: Uzi Ezra Havosha & Partners

20080160116 - Compositions and methods comprising zingiber species: An aspect of the present invention relates to compositions comprising a gingerol, for example, compositions comprising gingerol in an amount greater than about 2% by weight. In some aspects of the invention, the composition comprises 6-gingerol, 8-gingerol, 10-gingerol, 6-shagaol, or combinations thereof. Another aspect of the invention relates to a... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080160117 - Composition, a food, and a beverage having an anti-obesity action: Compositions, foods, and beverages which contain a salt-free or a reduced-salt fermented soybean paste-like food material in which the salt content is 5% or less, obtained by hydrolyzing soybean by a koji mold have an excellent anti-obesity action.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080160118 - Treatment of skin with cosmetic and dermatological preparations containing extracts from seeds of plants of the genus adenanthera: Methods of soothing, treating and/or relieving the skin, the scalp, and/or the hair as a result of UV radiation and other oxidative and/or other environmental irritations, pollutions, stresses and damage, itching and/or flaking, including dandruff, or dry skin, inflammation, including rosacea, and/or against wrinkling and other signs of aging, with... Agent: Cognis Corporation Patent Department

20080160119 - Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect: The objective of the present invention is to identify compounds having an inhibitory effect on adipocyte differentiation, and to provide pharmaceutical compositions and food compositions for prevention, improvement, or treatment of obesity or obesity related diseases. By enthusiastically studying natural products that inhibit the differentiation induction of adipocyte precursors into... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080160120 - Lapactic agent: MEANS TO SOLVE THE PROBLEMS: A lapactic agent comprising (A) a basic polymer and/or the salt thereof, and (B) a dietary fiber, wherein (A) a basic polymer and/or the salt thereof is at least one selected from the group consisting of polyvinylamine, polyallylamine, polyethyleneimine, polyvinylpyridine, poly (N,N-dimethylaminoethyl acrylate), ε-polylysine, a... Agent: J.c. Patents

20080160121 - Intracranial botulinum toxin therapy for focal epilepsy: Methods for treating and/or curing epilepsy by intracranial administration of a botulinum toxin.... Agent: Allergan, Inc.